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ABSTRACT OF THE DISSERTATION
BACTERIAL MECHANISMS OF TOXICITY AND RESISTANCE TO
ORGANOARSENICALS
by
Luis D Garbinski
Florida International University, 2020
Miami, Florida
Professor Barry P. Rosen, Co-Major Professor
Professor Masafumi Yoshinaga, Co-Major Professor
Arsenic is a toxic element prevalent in the environment since the origin of life on
Earth. Bacteria evolved in an arsenic-rich environment, where they developed
ways to both overcome arsenic toxicity and harness it to compete with other
organisms. These mechanisms include chemical modifications (e.g. oxidation,
methylation), degradation, and efflux. The goal of this dissertation is to better
characterize these mechanisms, illuminating the arsenic biogeocycle and allowing
us to harness organoarsenical toxicity for novel antibiotics. A goal of my research
was to elucidate the antibiotic properties of MAs(III), which is synthesized by
bacteria to thrive over other bacteria, by identifying cellular targets involved in its
toxicity. I identified MurA, a key enzyme in bacterial cell wall synthesis, as a
potential target. I determined that MurA is inhibited by organoarsenicals, but not
by inorganic As(III), suggesting that these antibiotics kill bacteria by inhibiting cell
wall formation. I also determined that MAs(III) inhibits MurA differently than
fosfomycin, the conventional MurA-inhibitory antibiotic, highlighting the potential
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that organoarsenicals have as antibiotics. The most efficient bacterial resistance
mechanism to MAs(III) is efflux from cells, catalyzed by the ArsP permease. While
ArsP can transport aromatic organoarsenicals like trivalent roxarsone (Rox(III)), it
transports MAs(III) most efficiently. To further characterize ArsP, I probed its
substrate binding site by mutagenesis. I found that several conserved residues
hypothesized to be required for transport are in fact not required for resistance to
organoarsenicals. Furthermore, I determined that the higher affinity of Rox(III) for
cysteine pairs does not play a role in selectivity for MAs(III). Aromatic arsenicals
are widely used as growth promoters in animal husbandry and understanding their
degradation to As(III) by soil bacteria is critical to minimizing their environmental
hazards. We characterized their biotransformation by Sinorhizobium meliloti, and
identified an enzyme, MdaB, that catalyzes the first step of aromatic
organoarsenical degradation. Overall, we show how S. meliloti can activate benign
pentavalent aromatic arsenicals into more toxic species. Characterizing enzymes
and transporters involved in organoarsenical toxicity and resistance will help us
design novel arsenic bioremediation strategies, as well as develop effective
arsenic-based antibiotics that will contribute to human health and safety.
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CHAPTER 1. INTRODUCTION
1.1

Arsenic sources in the environment
Arsenic is the most pervasive environmental toxin, consistently ranked by

the Environmental Protection Agency (EPA) and Agency for Toxic Substances and
Disease Registry (ATSDR) as the highest priority pollutant based on its occurrence
and

toxicity

in

contaminated

national

priority

list

(NPL)

sites

(https://www.atsdr.cdc.gov/spl/index.html). While mostly found in natural geology
(Christophersen et al., 2013), arsenic is a versatile element most commonly found
in four chemical forms: arsenate (+5), arsenite (+3), elemental arsenic (0), and
arsine (-3) (Oremland and Stolz, 2003). Under oxic conditions such as in aerobic
soils and surface waters, arsenic is found primarily in its pentavalent form as
arsenate (As(V)). Under reducing conditions, like those inside living organisms and
in flooded soils or anaerobic sediments, it is mostly found in its trivalent state as
arsenite (As(III)) (Zhu et al., 2014).
Importantly,

arsenic

is

also

introduced

into

the

environment

anthropogenically (Figure 1), including synthetic organoarsenicals used as
antimicrobial growth promoters in livestock and as herbicidal agents, and as alloys
with other metals in various industrial processes such as semiconductor
manufacturing, chemical treatment of lumber, and the production of paints and
pharmaceuticals (Adachi, 1985; Razo et al., 2004; Khan et al., 2011;
Christophersen et al., 2013; Matteson et al., 2014). In particular, methylated
arsenicals like MSMA (monosodium salt of methylarsenate (MAs(V)) have long
been used as herbicides. Organic arsenical herbicides were widely used when
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they were introduced in the 1950s due to their low cost and toxicity compared to
the lead arsenate compounds they replaced (Zandstra and De Kryger, 2007).
MSMA was commonly applied in cotton fields, golf courses, and on turf and lawn.
Roughly 1.3 million kilograms of MSMA used in the US until EPA restrictions were
placed in 2014 (Chen et al., 2020a). The pentavalent aromatic arsenical roxarsone
(Rox(V)), was approved by the U.S. Food and Drug Administration (FDA) in 1944
as an additive for poultry feed, where it acts as an antimicrobial and a growth
promoter (Fisher et al., 2015). The USDA estimated that in 2010, 88% of the
approximately 9 billion chickens raised for human consumption in the US were
treated with roxarsone. Furthermore, a U.S. sample of raw and cooked chickens
showed that over 50% of the chicken meat analyzed contained arsenic
concentrations over 10 μg per kg (Nachman et al., 2013). It has been well
established that roxarsone is not fully metabolized by poultry and accumulates in
chicken litter (Jackson and Bertsch, 2001). Arsenic speciation of chicken litter
samples shows that roxarsone is degraded into As(III), among other species
(Rosal et al., 2005). Due to the environmental health concerns associated with
roxarsone usage, the FDA withdrew its approval in the US, though it continues to
be used worldwide.
1.2

The duality of arsenic

1.2.1 Arsenic toxicity
Due to its ubiquity, humans are frequently exposed to arsenic through the
food chain, in drinking water supply, and by contaminated soils. Around the world,
exposure to arsenic has been linked to cardiovascular disease (Wang et al., 2011;
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Chen et al., 2013), diabetes mellitus (Del Razo et al., 2011; Mendez et al., 2016),
and peripheral neuropathies (Mukherjee et al., 2003). Arsenic is classified as a
group 1 human carcinogen by the International Agency for Research on Cancer
(IARC), and has been linked to increased risks of liver, bladder, lung, and skin
cancer, among others (Chung et al., 2013; Gilbert-Diamond et al., 2013).
Furthermore, infant mortality, issues with fetal development, and neurological
defects have been associated with arsenic exposure. A cohort study in Bangladesh
described a significant correlation between sources of drinking water above 50 μg
per liter (or parts per million, ppm) and fetal loss (Rahman et al., 2007). For
children surviving birth in arsenic-contaminated environments, exposure is
associated with lowered cognitive and motor function (Calderón et al., 2001;
Parvez et al., 2011). As a response, the FDA has issued guidance limiting the
concentration of arsenic to 100 parts per billion (ppb) in infant foods, and 10 ppb
in fluids like apple juice and bottled water with the intent to lower the risk of these
outcomes. The FDA also regularly tests various at-risk products such as infant rice
cereals to ensure these limits are enforced (https://www.fda.gov/food/metals-andyour-food/arsenic-food-and-dietary-supplements). Arsenic toxicity is also variable
depending on its chemical form. In general (with few exceptions) trivalent
organoarsenicals are the most toxic, followed by As(III), and the least toxic being
pentavalent arsenicals and organoarsenicals (Petrick et al., 2000).
Arsenic poisoning can be acute or chronic, with the latter being more
pervasive (Ratnaike, 2003). Acute arsenic exposure is most commonly caused by
accidental ingestion of arsenic-containing pesticides or herbicides. Arsenic is also
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a potent agent used in poisons, and it is dubbed “the king of poisons” and “poison
of kings.” The primary arsenic species historically used for poisoning is arsenic
trioxide (As2O3), as it is colorless, odorless, and readily water-soluble.
(Parascandola, 2012). These poisons were popular among European nobility
around the fifteenth century, generally used for political or financial gain. Acute
arsenic toxicity is characterized by nausea, vomiting, and diarrhea (Ratnaike,
2003) and mortality is generally attributed to severe fluid loss due to increased
blood vessel permeability, renal failure, and pulmonary edema. The lethal dose for
this type of exposure is between 100 and 300 mg, though certain clinical cases
with many-fold higher doses reported temporary survival (Logemann et al., 1990;
Ghariani et al., 1991). Interestingly, acute arsenic poisoning by external use, in
contrast to ingestion, has also been reported (Zheng et al., 2019). Absorption of
ingested trivalent arsenic generally occurs in the GI tract, where aquaporins
mediate uptake from the lumen into epithelial cells (AQP7/10), and subsequently
transported into the bloodstream (AQP3) (Roggenbeck et al., 2016). It is unclear
whether at this step, the microbiome protects against arsenic toxicity or
exacerbates it. Recent reports have shown that arsenic species found in seafood
are more readily taken up and metabolized to more toxic intermediates in the
presence of the microbiota (Calatayud et al., 2018), while other studies show that
germ-free mice accumulate arsenic in tissues more readily after acute exposure,
and identify members of the microbiota that can rescue the sensitive phenotype
(Coryell et al., 2018).
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Due to its affinity for dithiol groups (Shen et al., 2013), several molecular
targets and pathways are inhibited by trivalent arsenic. Particularly, mitochondrial
redox proteins involved in apoptotic signaling and oxidative stress protection are
suggested to be targets of trivalent arsenicals (Ralph, 2008). Mitochondrial
thioredoxins (TRXs) 1 and 2 contain vicinal thiol groups which bind the proapoptotic protein ASK1, inactivating it. In the presence of tumor necrosis factor
(TNF) mitochondrial production of reactive oxygen species (ROS) is increased,
leading to oxidation of TRX1 and TRX2, which in turn activates ASK1 and initiates
apoptosis (Zhang et al., 2004). Trivalent arsenicals, especially MAs(III), bind with
very high affinity to TRX1/2 and TRX reductase, which also has a dithiol group
(Hansen et al., 2006), suggesting that ROS-mediated oxidative stress takes place
and can induce apoptosis similarly to TNF. Another mitochondrial apoptotic
pathway affected by trivalent arsenicals involves the voltage dependent anion
channel (VDAC) and the adenine nucleotide transporter (ANT) which together form
part of the mitochondrial permeability transition pore (MPTP) (Marzo et al., 1998).
Both of these proteins contain cysteine residues, and the redox state of thiol
groups has been linked to activation of mitochondrial permeability transition
(Costantini et al., 1996; Costantini et al., 2000). Furthermore, thiol-reactive
compounds like phenylarsine oxide (PAO), which has the highest affinity for
arsenic-binding enzymes of known trivalent species (Pawitwar et al., 2017), have
been shown to affect mitochondrial permeability by cross-linking two cysteines
which lock ANT in its open conformation (McStay et al., 2002), facilitating
mitochondrial apoptosis.
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While arsenic-driven ROS production in mitochondria has also been linked
to carcinogenesis (Huang et al., 2004), other oncogenic pathways can be altered
by chronic arsenic exposure. The phosphoinositide 3-kinase (PI3K)/protein kinase
B (AKT)/mammalian target of rapamycin (mTOR) pathway is a key pathway
involved in regulation of physiological processes such as cell proliferation,
metabolism and growth (Martini et al., 2014). Unsurprisingly, dysregulation of this
pathway is strongly linked to several hallmarks of cancer (Fruman et al., 2017).
As(III) has been shown to stimulate upstream genes such as the epidermal growth
factor receptor (EGFR) by inducing the assembly of EFGR-Shc-Grb2 complexes,
resulting in phosphorylation of EGFR. (Chen et al., 1998; Tanaka‐Kagawa et al.,
2003), While EGFR had been hypothesized to activate PI3K-AKT signaling by
interactions with the p85 regulatory subunit of PI3K, the effectors in the signaling
cascade were not well understood (Wen et al., 2010; Carpenter and Jiang, 2013).
Recently, EGFR was shown to activate the PI3K pathway by acetylation, and
subsequent phosphorylation of the platelet isoform of phosphofructokinase 1
(PFKP) (Lee et al., 2018). Phosphorylated PFKP directly interacts with the
regulatory subunit p85 of PI3K, recruiting it to the plasma membrane and thus
activating PI3K. This activation was shown to promote tumor cell proliferation and
brain tumorigenesis. Interestingly, organoarsenicals such as roxarsone can also
activate the PI3K/Akt pathway in mice, and that it acts a driver of angiogenesis,
explaining its activity as a growth promoter (Wang et al., 2016).
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Arsenate (As(V)) is significantly less toxic than As(III); however, it is the
most environmentally ubiquitous species of the two. As(V) is chemically similar to
phosphate, thus it can hijack many cellular processes which utilize phosphate. One
of the best characterized mechanisms of As(V) toxicity is impairment of energy
metabolism. Early studies hypothesized that in mitochondria, As(V) is incorporated
into ADP-arsenate, which acts as a substrate of with glycolytic enzymes such as
hexokinase and glyceraldehyde 3-phosphate dehydrogenase (GAPDH), forming
glucose 6-arsenate and 1-arseno-3-phosphoglycerate. These arsenate-based
sugars are unstable and hydrolyze rapidly, potentially explaining how As(V)
depletes cellular ATP (Byers et al., 1979; Gresser, 1981). Interestingly, GAPDH
acts as an arsenate reductase in the presence of glutathione (GSH) and its
canonical substrate, glyceraldehyde-3-phosphate (G3P) (Gregus and Németi,
2005), and has been described as part of a novel arsenate resistance mechanism
in bacteria when coupled to the transporter ArsJ (Chen et al., 2016).
1.2.2 Arsenic as a medicine
Throughout history, arsenic has also been used as a medicine. From
ancient Greeks using pastes made from natural arsenic-containing minerals such
as realgar (As4S4) and orpiment (As2S3) to treat ulcers (Healy, 1981), to the advent
of modern medicine with Paul Ehrlich’s “magic bullet” Salvarsan as a miraculous
cure to syphilis (Lloyd et al., 2005), arsenic-based drugs continue to be used today
as first-line therapies for several diseases. An example is arsenic trioxide, or ATO,
which when administered in combination with all-trans retinoic acid (ATRA) safely
treats acute promyelocytic leukemia (APL) (Kozono et al., 2018). In this
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combination therapy, ATO degrades the peptidyl-prolyl isomerase Pin1, which has
been characterized as a cell-cycle protein and involved in the regulation of several
oncogenes. ATRA upregulates aquaporin-9 (AQP9), which increases the cellular
uptake of ATO, enhancing its effects. Another possible explanation for the dual
modality of arsenic is that in comparison to normal cells, cancer cells are already
in a hyperproliferative state where the AKT/mTOR pathway is stimulated; thus,
ROS production by arsenic toxicity decreases phosphorylation of AKT and
promotes apoptosis. This has been demonstrated in osteosarcoma (Wang et al.,
2017), human gastric cancer cells (Gao et al., 2014), and in leukemia cells (Estañ
et al., 2012). The extent of this effect is highly dependent on arsenic species and
concentration (Wang et al., 2016). In fact, it has been suggested that the true
prodrug when administering ATO to treat APL is MAs(III), as ATO is likely rapidly
methylated by AS3MT and redistributed in the bloodstream (Maimaitiyiming et al.,
2020). Lastly, as seen with Salvarsan, arsenic-based drugs have great potential
as antimicrobial agents. Recently, our lab found that a newly discovered
organoarsenical compound, arsinothricin (Kuramata et al., 2016), is able to inhibit
the growth of several antibiotic-resistant pathogens (Nadar et al., 2019), by a novel
mechanism of action which will be discussed later. In contrast to the body of data
on molecular mechanisms of arsenic toxicity in mammalian cells, no bacteriaspecific target for arsenic antibiotics produced in the environment such as MAs(III)
has been described so far.
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1.3

Organoarsenicals and bacterial arsenic biotransformations
Since life first appeared on Earth it has been exposed to substantial

concentrations of inorganic arsenic, which over time, provided selective pressure
for the evolution of arsenic resistance pathways, and gave an opportunity for
members of microbial communities to harness its toxicity for their own competitive
advantage (Zhu et al., 2014; Chen et al., 2019a). Genes involved in bacterial
arsenic metabolism are generally found in ars operons (Table 1) (Silver et al.,
1981), and over the last decades, microbial arsenic transformations such as redox
cycling, methylation, thiolation, and incorporation into complex organic molecules
like arsenosugars and arsenolipids have been identified (Zhu et al., 2017). Prior to
the Great Oxidation Event (GOE) roughly 2.4 billion years ago, bacteria had to
detoxify mainly As(III), through either the As(III)-specific efflux pump Acr3, or the
As(III) S-adenosylmethionine methyltransferase (SAM) ArsM, where As(III) would
undergo three methylation cycles and become trimethylarsine (TMAs(III)), which
is a non-toxic gas (Qin et al., 2006; Fu et al., 2009; Chen et al., 2020b). Later,
bacteria evolved ArsP, an efflux pump that selectively transports the singlemethylated intermediate product of ArsM, methylarsenite (MAs(III)) (Chen et al.,
2015b). Recently, bacteria have been shown to gain a competitive advantage in
microbial communities when expressing both ArsM and ArsP, suggesting that
MAs(III) acted a primordial antibiotic (Chen et al., 2019a). Following the GOE,
As(III) in the environment would mostly be oxidized to As(V), reducing its toxicity.
Similarly, MAs(III) produced in bacterial communities would be oxidized to MAs(V),
a relatively benign organoarsenical. To regain their competitive advantage,
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bacteria evolved yet-to-be identified MAs(V) reductases which could “re-activate”
the antimicrobial activity of MAs(III) that was oxidized (Yoshinaga et al., 2011). As
a countermeasure, MAs(III)-sensitive bacteria evolved various mechanisms to
detoxify MAs(III) such as oxidases (Chen et al., 2015a) and C-As bond lyases
(Yoshinaga and Rosen, 2014), as well as acquiring arsP via horizontal gene
transfer.
In the last century, synthetic aromatic arsenic compounds such as
roxarsone (Rox(V)), nitarsone (Nit(V)), p-arsanilic acid (p-ASA(V)) and others,
were used as growth promoters and antimicrobial drugs in animal husbandry.
Interestingly, MAs(III) detoxifying enzymes thought to evolve over billions of years
also detoxify these new organoarsenicals. In fact, species such as Sinorhizobium
meliloti reduce aromatic arsenicals to trivalent forms to activate their antibiotic
properties (Yan et al., 2019), whereas other bacteria such as Burkholderia sp. MR1
and Pseudomonas putida KT2440 which are able to reduce MAs(V) to MAs(III)
(Yoshinaga et al., 2011), cannot reduce aromatic arsenicals. Recently, a threegene cluster (arsEFG) from Shewanella putrefaciens 200 conferring resistance to
trivalent aromatic arsenicals was identified (Chen et al., 2019b). Every gene was
required for resistance to Rox(III), and cells expressing this cluster were observed
to reduce the nitro group of Rox(III). This reduction is likely catalyzed by both ArsE
and ArsF, though the exact mechanism of reduction is not yet known. Neither of
these proteins are related to the well-studied families of NAD(P)H-dependent
nitroreductases, and it is likely that they belong to a new class of nitroreductases.
However, as suggested by Yan et al, if reduction of the nitro group of aromatic
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arsenicals activates their antimicrobial properties, how could this cluster confer
resistance? An explanation may be that the third gene, arsG, encodes a
membrane protein that reduces intracellular accumulation of the products of ArsE
and ArsF. This transporter will be discussed in more detail later (Chen et al.,
2019b). Interestingly, a nitroreductase from Pseudomonas putida has recently
been shown to confer resistance to trivalent aromatic arsenicals when expressed
in arsenic-hypersensitive E. coli (Chen and Rosen, 2020). This brings to question
whether nitroreductases can both play a part in aromatic organoarsenical
detoxification pathways, as well as activating their antibiotic properties.
In marine environments, arsenic-containing ribosides, also known as
arsenosugars are synthesized by coupling As(III) methylation to the addition of a
deoxyribose moiety by the radical SAM protein ArsS was identified in
cyanobacteria (Xue et al., 2018). As arsenosugars are nontoxic to marine plants
or animals, this process is considered a detoxification mechanism. Similarly,
arsenic can be incorporated into lipid-soluble long aliphatic chains such as
hydrocarbons, fatty acids, and phospholipids, generally termed arsenolipids.
Though several species of arsenolipids have been identified (Chen et al., 2020a),
and arsenosugar-containing phospholipids have been observed in certain alga
(suggesting a linked metabolic pathway between arsenosugar and arsenolipid
production), their biosynthetic pathway remains unclear. While arsenosugars and
arsenolipids are nontoxic to marine life, degradation of these compounds to
inorganic As has been reported in marine bacteria (Foster and Maher, 2010).
Furthermore, the primary metabolite of microbiome-mediated degradation of these
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compounds is dimethylated arsenic (DMAs) (Figure 1) (Francesconi et al., 2002),
which can be thiolated to dimethyl monothiol arsenate (DMMTAs(V)), shown to be
highly toxic in human cell cultures (Naranmandura et al., 2009).
Recently, a novel arsenic-containing glutamate analog was isolated from
the rice rhizosphere bacterium Burkholderia gladioli GSRB05 (Kuramata et al.,
2016). This compound, named arsinothricin (AST), is an arsenic analog of the
phosphonate compound phosphinothricin (PT) which has herbicidal and
bactericidal properties (Hoerlein, 1994). AST acts as a glutamine synthetase
inhibitor because it mimics the γ-phosphoglutamate transition state intermediate,
and has higher antibiotic properties compared to PT, and even to As(III), which is
unusual for pentavalent organoarsenicals (Nadar et al., 2019). In addition, arsN1,
a gene present in many ars operons encodes an N-acetyltransferase that confers
resistance to AST, and is selective for AST over PT. This recent finding
demonstrates that there are likely many yet-to-be discovered arsenic-based
antibiotics which could be harnessed to combat the rising threats of antimicrobial
resistance.
1.4

Bacterial arsenic transport
Bacteria evolved efflux pumps and transporters that confer resistance to

toxic compounds (Li et al., 2015). Having been exposed to arsenic, a toxic, nonessential element since the dawn of life, bacteria have evolved efflux transporters
with varying substrate selectivity/specificity (Garbinski et al., 2019). Nearly every
ars operon contains a gene encoding for either or both known inorganic As
transporters, the As(III)-specific antiporter Acr3, which is widely distributed among
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bacteria, plants, and fungi (Fu et al., 2009), and the As(III)/Sb(III) antiporter ArsB
(Rosen, 1990; Fu et al., 2009; Zhu et al., 2014; Chen et al., 2020b). Biosynthesis
of MAs(III) in microbial communities also applied evolutionary pressure for bacteria
to evolve efflux mechanisms selective for this organoarsenical antibiotic. The first
organoarsenical transporter in bacteria to be identified and characterized was ArsP
(Shen et al., 2014; Chen et al., 2015b). ArsP catalyzes extrusion of MAs(III),
providing resistance to the producer strain of this ancient antibiotic. Recently three
other organoarsenical efflux permeases have been identified. First, ArsK is a
permease for both MAs(III) and As(III) (Shi et al., 2018). Second, ArsJ is an efflux
transporter for the unstable organoarsenical 1-arseno-3-phosphoglycerate
(1As3PGA), which is produced by the enzyme glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), a novel As(V) resistance pathway (Chen et al., 2016).
The third is ArsG, a 3-amino-4-hydroxybenzene arsonic acid (HAPA)/p-arsanilic
(p-ASA) efflux permease that is part of a Rox(III)/Nit(V) detoxification pathway
(Chen et al., 2019b).
1.4.1 As(III) efflux systems
The arsB gene, which encodes the ArsB efflux transporter, was among the
first identified bacterial arsenic resistance genes (Tisa and Rosen, 1990).
Originally isolated from the E. coli R-factor R773, which showed reduced
intracellular accumulation of As(III) (Rosen and Borbolla, 1984), ArsB is the
membrane spanning subunit of the ArsAB ATPase, which transports As(III) and
Sb(III) (Rosen et al., 1999). ArsB belongs to the ion transporter superfamily
(Achour et al., 2007), though predictions of its membrane topology and early
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studies suggest that it has 12 membrane spanning domains (Wu et al., 1992;
Garbinski et al., 2019) raising the possibility that it belongs to the major facilitator
superfamily (MFS) of transporters. ArsB is unique among arsenic transporters in
two ways: it has two distinct mechanisms of transport depending whether or not it
is coupled to the ArsA ATPase. The As(III) binding site in ArsB has not been
identified. It has no required cysteine residues, which frequently form As(III)
binding sites (Chen et al., 1996). By itself, ArsB is an antiporter which utilizes the
proton motive force to exchange protons for As(III)/Sb(III) (Meng et al., 2004).
Furthermore, when everted vesicles expressing ArsB are exposed to both As(III)
and Sb(III), As(III) inhibits Sb(III) uptake while Sb(III) stimulates As(III) uptake
(Meng et al., 2004); a paradoxical finding which suggests trihydroxides are not the
substrates of ArsB. Instead, it is possible these substrates polymerize like their
phosphate analogs, which has been observed for As(III) (Hampson and Stosick,
1938), and are transported by ArsB as polymeric species. When the ArsA ATPase
is present, ArsAB acts as an ATP-driven As(III)/Sb(III) efflux pump, greatly
increasing the rate of transport and resistance in E. coli (Dey and Rosen, 1995).
The ArsA metal-binding sites is comprised of three conserved cysteines (Cys422,
Cys113, and Cys172), that on substrate binding induce a conformational change
which brings two nucleotide-binding domains (NBD) close enough together to
catalyze ATP hydrolysis (Zhou et al., 2000). Individual cysteine-to-serine
mutations of these residues yielded lower affinities for Sb(III) and As(III) compared
to the wild-type, suggesting that each residue is involved in catalysis
(Bhattacharjee et al., 1995).
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Acr3 is the most ancient known As efflux transporter having evolved well
before the GOE, presumably as one of the first As(III) resistance mechanisms
(Chen et al., 2020b). While ArsB and Acr3 are both efflux systems for As(III), they
have key functional and structural differences. Acr3 is smaller than ArsB (~357
residues vs. ~429 of ArsB), and belongs to the bile/arsenite/riboflavin transporter
(BART) superfamily, which consists of bile salt and anion transporters, as well as
sensory proteins such as kinases (Mansour et al., 2007). As(III) is transported out
of cells by Acr3 as an As(III)/H+ antiporter (Villadangos et al., 2012). Heterologous
expression of Acr3 from Corynebacterium glutamicum (CgAcr3) in Escherichia coli
confers As(III) resistance, while E. coli cells expressing CgAcr3 with the highly
conserved Cys138 mutated to serine or alanine are sensitive to As(III), suggesting
that Cys138 is essential for CgAcr3 to be functional (Fu et al., 2009). Everted
vesicles prepared from E. coli cells expressing wild-type CgAcr3 accumulate
As(III), whereas those of C138S/A mutant cells accumulate no As(III), which further
supports the critical role of Cys138 for CgAcr3. Members of the BART superfamily
are predicted to either have ten membrane-spanning segments, or two subunits of
five membrane-spanning segments (Mansour et al., 2007). The topology of
CgAcr3 is congruent with these predictions, and has been shown to have ten
membrane-spanning segments (Fu et al., 2009). In addition, many arsenic-binding
proteins, including efflux transporters, can also bind antimonite (Sb(III)) (Rosen,
1990; Wu and Rosen, 1991); however, Acr3 is As(III)-specific, and cannot
transport nor confer resistance to Sb(III). There are conflicting reports on Sb(III)
accumulation and resistance in Acr3 homologs found outside of bacteria, such as
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the Saccharomyces cerevisiae ACR3 (Ghosh et al., 1999; MaciaszczykDziubinska et al., 2011). Interestingly, the yeast ACR3 has 9 cysteines compared
to the 3 of bacterial Acr3 proteins like that of A. metalliredigens (Fu et al., 2009).
1.4.2 As(V) efflux systems
With the exception of AST and thiolated species, pentavalent arsenicals are
significantly less toxic than their trivalent counterparts. However, arsenate (As(V))
is a mimetic of phosphate, and can be taken up by bacterial phosphate
transporters adventitiously (Garbinski et al., 2019). With As(V) being the most
environmentally prevalent species of arsenic especially in the oxic environment
(Zhu et al., 2014), it is likely that bacteria encounter toxic concentrations of it
frequently. A pair of genes always found together in ars operons, arsJ and gapdh,
encoding a major facilitator superfamily (MFS) protein and Glyceraldehyde 3phosphate dehydrogenase, respectively, were isolated from Pseudomonas
aeruginosa DK2 and characterized (Chen et al., 2016). Both genes are required tp
confer E. coli As(V) resistance. ArsJ-mediated As(V) uptake into everted vesicles
was found to be energized by the proton motive force, and required GAPDH,
NAD+, and 1,3-biphosphoglycerate (G3P), the substrate for the GAPDH reaction.
GAPDH normally catalyzes the conversion of G3P and NAD+ to 1,3bisphosphoglycerate (1,3-BPG) and NADH, but in the presence of As(V) it can
form

the

highly

unstable

organoarsenical

1-arseno-3-phosphoglycerate

(1As3PGA) (Byers et al., 1979). Because the transport reaction requires both
GAPDH and NAD+ (Chen et al., 2016), it is likely that 1As3PGA is the physiological
substrate of ArsJ. This is an unusual example of how bacteria adapt existing
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proteins to fit physiological needs, as evolving a direct As(V) transporter would
likely deplete bacterial cells of necessary phosphate. This is the only identified
As(V)-specific efflux mechanism.
1.4.3 Organoarsenical transporters
While Acr3 and ArsB are the primary efflux systems for As(III), they do not
transport organoarsenicals. In addition to ArsJ, there are several more known
organoarsenical efflux permeases – ArsP, ArsK and ArsG. The arsP gene was
first identified from poultry isolates of the food-borne pathogen Campylobacter
jejuni (Wang et al., 2009). Initially, it was described as encoding a
roxarsone/nitarsone resistance mechanism (Shen et al., 2014), as these
organoarsenicals were commonly used as antimicrobials and growth promoters in
the poultry industry. However, further studies demonstrated that the physiological
substrates of ArsP are not pentavalent organoarsenicals but trivalent forms and
the true substrate of ArsP is likely to be MAs(III), as the transport efficiency and
resistance conferred by ArsP to MAs(III) was significantly greater than to trivalent
roxarsone/nitarsone (Chen et al., 2015b). Furthermore, two conserved cysteine
residues (Cys65 and Cys67) were identified as the putative arsenic-binding site,
as mutating these residues to serine ablated transport and resistance while
retaining expression. ArsP is hypothesized to belong to the major facilitator
superfamily (MFS) of transporters (Garbinski et al., 2019); however, this is a topic
of debate as transmembrane topology prediction algorithms predict that ArsP only
has eight membrane-spanning helices, compared to the usual twelve of MFS
transporters. ArsP is hypothesized to transport organoarsenicals in a two-step
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mechanism, with the first step being an inward-facing conformation where the
conserved cysteines are close enough for arsenic binding, followed by an outwardfacing conformation where the cysteines separate, and substrate is carried out of
the cell (Chen et al., 2015b). This hypothesis also predicts that bulkier
organoarsenical compounds like roxarsone and nitarsone are transported with
lower efficiency due to steric hindrance of the substrate binding site. Further
studies are required to comprehensively elucidate the transport mechanism of
ArsP.
Recently, ArsK, an organoarsenical transporter with wider substrate
specificity, was identified in the soil bacterium Agrobacterium tumefaciens GW4
(Shi et al., 2018). This permease transports both trivalent inorganic and organic
arsenicals, as well as inorganic antimony, out of cells. Phylogenetic analysis
suggest that ArsK is an MFS transporter but is classified in a new subgroup in the
family of MFS transporters (Garbinski et al., 2019). ArsK is found in ars operons
that encode resistance mechanisms to both inorganic and organic arsenicals (Shi
et al., 2018). In contrast to ArsP, ArsK is observed to transport trivalent aromatic
arsenicals such as Rox(III) with higher efficiency than MAs(III), suggesting that
there are yet-to-be discovered aromatic arsenic natural products which may be its
primary substrate. There are conserved cysteine residues found in ArsK (Cys97
and Cys182); however, it remains unclear whether they play a role in transport.
Aromatic arsenical compounds like roxarsone, nitarsone, and p-arsanilic
acid (p-ASA) are synthetic organic compounds used only since the last century, so
it is unlikely that bacteria had time to evolve specific resistance genes but more
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likely adapted existing genes. As mentioned above, recently a three gene cluster,
arsEFG, of unknown function, was identified in the versatile arsenic-metabolizing
soil bacterium Shewanella putrefaciens 200 (Chen et al., 2019b). These three
genes, encode a two-step pathway for resistance to trivalent nitroaromatic
arsenicals: 1) reduction of the nitro (NO2) group to an amino (NH2) group, and 2)
efflux of the trivalent product. ArsG was identified as a permease that transports
the final product out of the cell. Interestingly, ArsG is specific for trivalent HAPA(III)
over Rox(III), suggesting that the ArsG substrate-binding site is not solely
dependent on soft metal thiol chemistry. Further studies are necessary to confirm
the efflux mechanism of ArsG, as no residues critical for transport have been
identified yet. The existence of this aromatic arsenical-specific detoxification
mechanisms suggests that: 1) bacteria are able to acquire resistance to
environmentally prevalent toxins much quickly than previously thought, or 2) there
are natural, yet-to-be discovered aromatic arsenical compounds that are
synthesized in microbial communities which are the true substrates of ArsEFG.
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1.5

Figures and tables

Figure 1: Anthropogenic sources of arsenic and their biotransformations in the environment.
Metabolism of organoarsenicals in the body.
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Table 1. List of ars genes, the proteins they encode, and their functions.
Gene
arsA

Protein
Catalytic subunit of ArsAB As(III)
ABC transporter

Function
Energize As(III) efflux by ATP hydrolysis

Reference
(Rosen, B.P., et al. 1999)

arsB

Membrane subunit of the ArsAB
ABC transporter, H+/As(III)/Sb(III)
antiporter

Efflux of Sb(III)/As(III)

(Kuroda, M., et al. 1997)

arsC

Grx/Trx-dependent As(V) reductase

Detoxify As(V) by reduction to As(III) followed
by efflux

(Martin, P., et al. 2001)

arsD

As(III)/Sb(III) metallochaperone

Transfer As(III)/Sb(III) to ArsA for efflux

(Lin, Y-F., et al. 2006)

arsE

Trx-like Nit(III)/Rox(III)
nitroreductase

Nitroreduction of Rox(III) and Nit(III) to
HAPA(III) and p-ASA(III), respectively

(Chen, J., et al., 2019)

arsF

Trx-like Nit(III)/Rox(III)
nitroreductase

Nitroreduction of Rox(III) and Nit(III) to
HAPA(III) and p-ASA(III), respectively

(Chen, J., et al., 2019)

arsG

LysE superfamily transporter

p-ASA(III)/HAPA(III) efflux

(Chen, J., et al., 2019)

arsH

NADPH-dependent FMN
oxidoreductase

Detoxify trivalent organoarsenicals by
oxidation to pentavalent state

(Chen, J., et al., 2015)

arsI

Nonheme iron-dependent
dioxygenase

Detoxification of trivalent organoarsenicals by
C-As bond cleavage

(Yoshinaga, M. and Rosen,
B.P., 2014)

arsJ

MFS transporter

Efflux of 1As3PGA product of GAPDH as part of
As(V) resistance pathway

(Chen, J., et al., 2016)

arsK

MFS transporter

Efflux of As(III), Sb(III), Rox(III), and MAs(III)

(Shi, K., et al., 2018)

arsL

Radical SAM protein

Synthesis of the glutamate analog AST

Not yet published

arsM

As(III)-S-adenosylmethyltransferase

Detoxification of As(III) by three rounds of
methylation to gaseous TMA(III)

(Qin, J., et al., 2006)

arsN

AST-selective N-acetyltransferase

Confers resistance to AST by acetylation of αamino group

(Nadar, V.S., et al., 2019)

arsO

Putative
oxidoreductase/monooxygenase

Function unknown

(Maizel, D., et al., 2016)
(Wang, L., et al., 2006)

arsP

MAs(III)-selective efflux permease

Detoxifies trivalent aliphatic and aromatic
organoarsenicals by efflux

(Chen, J., et al., 2015)

arsQ

Putative MFS transporter

Function unknown

(Chauhan, N.S., et al., 2009)

arsR

ArsR/SmtB metalloregulator

Transcriptional repressor of ars operons

(Wu, J. and Rosen, B.P., 1993)

arsS

Radical SAM protein

Transfer of a deoxyadenosyl group from SAM
to DMAs for arsenosugar biosynthesis

(Xue, X-M., et al., 2019)

arsT

Putative thioredoxin reductase

Function unknown

(Achour, A., et al., 2010)

arsU

Putative arsenic resistance
mechanism

Function unknown

(Zhang, X., et al., 2016)

arsX

Putative thioredoxin

Function unknown

(Achour, A., et al., 2010)

arsY

H /As(III) antiporter (Acr3)

Detoxify As(III) by gradient-dependent efflux

(Yang, Y., et al., 2015)

+
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CHAPTER 2. PROBLEM STATEMENT AND OBJECTIVES
2.1

Problem statement
The arsenic biogeocycle is a complex network of redox cycles, microbial

biotransformations, and human activity. Arsenic is associated with several
negative health outcomes, including heart disease, diabetes, neuropathies, and
cancer (Kuo et al., 2017), while at the same time being the first line of treatment
for diseases such as acute promyelocytic leukemia. Microbial organoarsenic
synthesis and metabolism is a relatively new area. Finding novel arsenic
detoxification pathways and arsenic-based antibiotics (Nadar et al., 2019) broadly
expands our capacity to design better arsenic bioremediation strategies and to
harness its toxic properties to fight infectious diseases. Recently, we showed that
the synthesis of MAs(III) in bacterial communities confers a competitive advantage
to the producer strain (Chen et al., 2019); however, the molecular target in bacteria
responsible for its antimicrobial activity has not yet been identified. To understand
how trivalent organoarsenicals are so much more toxic than As(III), at least one
target specific to MAs(III) must be found. Furthermore, while ArsP has been
described as an MAs(III)-selective pump (Chen et al., 2015), neither the basis for
its selectivity nor its structural characteristics have been elucidated. These
properties are key to explain how enzymes that evolved billions of years ago are
able to detoxify synthetic aromatic arsenical compounds only several decades old.
Lastly, while the degradation pathways for aliphatic organoarsenicals like MAs(V)
have been outlined (Yoshinaga et al., 2011; Yoshinaga and Rosen, 2014), it is
hypothesized that other enzymes and possible separate pathways are involved in
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the degradation of nitroaromatic organoarsenicals like Rox(V) and Nit(V). One
difference

between

the

degradation

of

aliphatic

versus

nitroaromatic

organoarsenicals is the observed reduction of the nitro group in aromatic
arsenicals. Identifying an enzyme involved in this process will allow us to piece
together a more complete picture of how these man-made arsenicals are degraded
in soil and help us better predict their potential as environmental pollutants.
2.2

Project objectives are the following:
 Describe the organoarsenical biotransformation capacity of S. meliloti
Rm1021 and identify one enzyme involved in this process.
 Identify a molecular target associated with MAs(III) toxicity and characterize
its inhibition by MAs(III).
 Probe the substrate binding site of ArsP and assess whether highly
conserved residues impact its selectivity or resistance for MAs(III) over
aromatic organoarsenicals.
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Chapter 3.

3.1

REDUCTION OF ORGANOARSENICAL HERBICIDES AND
ANTIMICROBIAL GROWTH PROMOTERS BY THE LEGUME
SYMBIONT SINORHIZOBIUM MELILOTI

Introduction
The metalloid arsenic, the most pervasive environmental toxin, has exerted

selective pressure on organisms since life emerged on the Earth, which has led to
the evolution and acquisition of arsenic resistance mechanisms in nearly every
extant organism. In particular, bacteria have evolved a variety of unique ars genes
(Zhu et al., 2014; Zhu et al., 2017). One such gene is arsM, which encodes the
ArsM As(III) S-adenosylmethionine methyltransferase (Qin et al., 2006). ArsM
evolved before the GOE and generates reduced methylarsenicals such as
methylarsenite (MAs(III)) and dimethylarsenite (DMAs(III)) (Li et al., 2016; Chen et
al., 2017). These trivalent methylated arsenic species are much more toxic than
the inorganic forms and stable in anoxic environments, and we have proposed that
these ancient microbes activated available arsenic into more toxic forms for use
as antibiotics to kill competitors (Li et al., 2016; Chen et al., 2019a). In the present
oxic biosphere, arsenic methylation primarily functions as a detoxification
mechanism because trivalent methylarsenicals are rapidly oxidized to relatively
nontoxic methylarsenate (MAs(V)) and dimethylarsenate (DMAs(V)) (Qin et al.,
2006). In response, other bacteria revived the antibiotic strategy by re-reducing
MAs(V) to the trivalent form. Other bacteria responded by evolving multiple
mechanisms of resistance to the antibiotic action of MAs(III): by oxidation,
demethylation, or extrusion (Li et al., 2016; Chen et al., 2019a).
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Methylated arsenic species are introduced into the environment not only
through biogenic sources but also as a result of anthropogenic activities. In the
United States, a massive amount of methylarsenicals, both MAs(V) and DMAs(V),
have been utilized as herbicides since the early 1970s. Although the use of
DMAs(V) has been prohibited since the beginning of 2014 under the cancellation
order issued by the U.S. Environmental Protection Agency, the monosodium salt
of MAs(V), or MSMA, is still allowed for use on cotton fields, golf courses, sod
farms, and highway rights of way nationwide except in Florida, where the use is
now banned in golf courses (Gannon and Polizzotto, 2016).
In addition to MSMA, synthetic pentavalent aromatic arsenicals, including
Rox(V), nitarsone [4-nitrophenylarsenate; Nit(V)] and p-arsanilic acid [4aminophenylarsenate; p-ASA(V)] have been widely used since the 1940s,
especially in the poultry industry, as a feed additive to control protozoan parasitic
diseases and promote growth. Approximately, 2 000 000 pounds of Rox(V) were
released annually into the environment as manure from Rox(V)-fed animals, and
the manure was applied as a fertilizer for farm crops (Garbarino et al., 2003).
Although use of these aromatic arsenical growth promotors is no longer allowed in
the

United

States

(https://www.fda.gov/animal-veterinary/product-safety-

information/arsenic-based-animal-drugs-and-poultry), these compounds are still in
use in other countries (Huang et al., 2019). A large portion of these anthropogenic
organoarsenic compounds gradually degrade into more toxic inorganic forms
through microbial activities that impact the environment and contaminate our water
and food supplies (Feng et al., 2005; D'Angelo et al., 2012; Yao et al., 2016). A
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number of bacterial species, both aerobes (Quinn and McMullan, 1995; Lehr et al.,
2003; Maki et al., 2006; Huang et al., 2019) and anaerobes (Fisher et al., 2008;
Chen and Rosen, 2016; Han et al., 2017) have been documented to degrade
methyl and aromatic arsenicals; however, the pathways and molecular
mechanisms for degradation of organoarsenicals remain poorly understood.
We previously identified a microbial community from Florida golf course soil
that degrades MAs(V) aerobically (Yoshinaga et al., 2011), where one microbe
activates MAs(V) into highly toxic MAs(III) that other member subsequently
detoxifies into less toxic inorganic As(III). MAs(III) demethylation is catalyzed by
ArsI C–As lyase, an Fe(II)-dependent dioxygenase (Yoshinaga and Rosen, 2014).
Here,

we

demonstrate

that

pentavalent

aromatic

arsenicals

are

also

biotransformed into inorganic species via sequential reduction and ArsI-catalyzed
C–As bond cleavage by aerobic microbial communities, similar to the pathway of
demethylation of the MSMA herbicide. The legume symbiont Sinorhizobium
meliloti Rm1021 is a typical soil bacterium and forms nitrogen-fixing symbiosis with
alfalfa and other legumes. S. meliloti Rm1021 has been extensively studied as a
model organism for the genetic analysis of symbiotic nitrogen fixation and legume–
microbe interaction. Sequencing of the entire genome of S. meliloti Rm1021 has
been completed in 2001 (Galibert et al., 2001; Yang et al., 2005). For As
metabolism, S. meliloti Rm1021 can utilize a unique detoxification pathway
wherein reduction of As(V) by arsenate reductase (ArsC) is coupled to downhill
transport of As(III) through the aquaglyceroporin (AqpS) channel (Yang et al.,
2005). In this study, we demonstrate that S. meliloti Rm1021 reduces both MAs(V)
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and pentavalent aromatic arsenicals, producing trivalent methyl and aromatic
arsenicals. Other Rox(V)-degrading aerobes (Huang et al., 2019) and anaerobes
(Fisher et al., 2008; Chen and Rosen, 2016; Han et al., 2017) have been reported
to reduce the nitro group of nitroaromatic arsenicals such as Rox(V) and Nit(V).
We found that S. meliloti Rm1021 also reduces the nitro groups of Rox(V) and
Nit(V)

to

form

the

corresponding

aromatic

amines

4-hydroxy-3-

aminophenylarseate (HAPA(V)) and p-ASA(V), respectively. The arsenic in these
species is subsequently reduced, producing trivalent HAPA(III) and p-ASA(III),
which are much more toxic compared to the corresponding pentavalent species
(Chen et al., 2015a). When cells of S. meliloti Rm1021 were co-cultured with
Streptomyces sp. MD1, an MAs(III)-demethylating species isolated from Florida
golf course soil (Yoshinaga et al., 2011) degraded both methyl and aromatic
pentavalent arsenicals into inorganic As(III). Further, we identified mdaB, the gene
for the first reduction step, nitroreduction of nitroaromatic arsenicals, and
characterized the gene product MdaB (modulator of drug activity B) both in vivo
and in vitro.
3.2

Materials and methods

3.2.1 Strains and chemicals
S. meliloti Rm1021 (Meade et al., 1982) and its derivative strain RmP310
that lacks the chromosomal ars operon (Δars) (Yang, 2008; Chen et al., 2015a),
Pseudomonas putida KT2440 (Bagdasarian et al., 1981), Burkholderia sp. MR1,
and Streptomyces sp. MD1 (Yoshinaga et al., 2011) were used to analyze
biotransformation and uptake of organoarsenicals. Escherichia coli strain TOP10

40

(Invitrogen, Waltham, MA) was used for plasmid construction and replication. E.
coli strains AW3110(DE3) (Δars) (Carlin et al., 1995) and BL21(DE3) (Novagen,
Madison, WI) were used for analysis of activity of nitroreductases in vivo and
protein expression, respectively. Except where specified, bacterial strains were
cultured aerobically with shaking at 37 °C (E. coli strains) or 30 °C (others). Unless
otherwise indicated, all chemicals were of analytical or better grade from
MilliporeSigma (Burlington, MA). Rox(V) and HAPA(V) were purchased from
Thermo Fisher Scientific (Waltham, MA) and Pfaltz & Bauer (Waterbury, CT),
respectively. The trivalent organoarsenicals [Rox(III), Nit(III), p-ASA(III), and
HAPA(III)] were prepared by chemical reduction of their corresponding pentavalent
forms as previously described (Yoshinaga and Rosen, 2014). In brief, 0.2 mM
pentavalent arsenical was mixed with 27 mM Na2S2O3, 66 mM Na2S2O5, and 82 mM
H2SO4, following which the pH was adjusted to 6 with NaOH. We confirmed by
absorption spectroscopy that the chemical reduction method reduces As(V) to
As(III) but does not reduce the nitro group of roxarsone and nitarsone. The
methylarsonous acid iodide derivative (MAs(III)I2) synthesized as described (Stice
et al., 2016) was used as MAs(III). For confirmation purpose, prepared MAs(III)I2,
p-ASA(III), and HAPA(III) were treated with 4.5% (v/v) H2O2 and incubated first for
10 min at room temperature and further for 5 min at 80 °C. Oxidized
organoarsenicals were analyzed by HPLC-ICP-MS as described below to confirm
they match the corresponding pentavalent species (Figure 2A,C,F). The chemical
structures of arsenicals are shown in Figure 3.
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3.2.2 Biotransformation of organoarsenicals
S. meliloti Rm1021, S. meliloti RmP310 (Δars), Burkholderia sp. MR1,
and P. putida KT2440 were solely cultured with 1 μM MAs(V), p-ASA(V), Nit(V), or
Rox(V) in ST 10–1 medium (Maki et al., 2004) supplemented with 0.2% D-glucose,
2.5 mM CaCl2, and 2.5 mM MgSO4 for 3 days. As shown by our present results, S.
meliloti Rm1021 displayed an activity to reduce MAs(V), p-ASA(V), Nit(V), and
Rox(V) while it had a poor ability to degrade them into As(III). Our previous study
has shown that C–As lyase (ArsI) is responsible for degradation of trivalent
organarsenicals into As(III) (Yoshinaga and Rosen, 2014). Therefore, we cocultured S. meliloti Rm1021 with Streptomyces sp. MD1, a soil bacterium isolated
from golf course soils that contains arsI gene in its genome (Yoshinaga et al.,
2011; Yoshinaga and Rosen, 2014) to investigate the complete degradation
pathway of pentavalent organoarsenicals into inorganic arsenic. For coculture
experiments, S. meliloti Rm1021 and Streptomyces sp. MD1 were first cultured
separately for 24 h and then cocultured in the presence of pentavalent
organoarsenicals for an additional 3 days. We independently repeated the
bacterial culture/coculture experiment three times. Each culture was centrifuged at
13 400 × g for 1 min, and the supernatant solution was immediately filtered by
Amicon Ultra Centrifugal Filters with a 3000 Da cut-off membrane (MilliporeSigma).
The arsenic species in the filtrates were determined by high-performance liquid
chromatography (HPLC) (Series 2000; PerkinElmer, Waltham, MA) coupled to
inductively coupled plasma mass spectrometry (ICP-MS) (ELAN DRC-e;
PerkinElmer) using the previous instrument parameters (Yoshinaga and Rosen,
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2014). Briefly, MAs(V), p-ASA(V), HAPA(V), and their trivalent forms were
analyzed with Thermo Fisher Scientific BioBasic 18 LC column (250 mm × 4.6 mm,
5 μm, 300 Å) isocratically eluted with a mobile phase consisting of 3 mM malonic
acid and 5% methanol (v/v) (pH 5.95 for MAs and 5.2 for p-ASA and HAPA,
adjusted by tetrabutylammonium hydroxide), with a flow rate of 1 mL min–1 at 25
°C. Nit(V), Rox(V) and their trivalent forms were analyzed with the Inertsil C4
column (150 mm × 2.1 mm; 5 μm; GL Sciences, Japan) isocratically eluted with a
mobile phase consisted with 15% acetonitrile (v/v), 5% ethanol (v/v), and 80%
water (pH 1.5 adjusted by HCl) (v/v), at a flow rate of 0.3 or 0.6 mL min–1 at 60 °C.
For confirmation purpose, samples containing MAs(III), p-ASA(III), and HAPA(III)
were treated with 4.5% (v/v) H2O2 and incubated first for 10 min at room
temperature and further for 5 min at 80 °C. Oxidized samples were analyzed by
HPLC-ICP-MS to confirm their species (Figure 2B,D,E,G). Each amount of the
indicated arsenic species in bacterial culture/coculture samples was quantified
from the corresponding peak area using Chromera Chromatography Data System
version 2.1 (PerkinElmer) according to standard curves prepared with standard
solutions in the range of 0.5–2 μM in water. The results from the triplicated
independent experiments are summarized in Table S1.
3.2.3 Plasmid construction
By conducting a BLAST (Basic Local Alignment Search Tool) search of the
genome of S. meliloti 1021, the genes encoding SmAzoR (NCBI accession no.:
NP_385442),

SmMdaB

(NP_387022),

SmMsuE

(NP_438025),

SmNemA

(NP_385670), SmAZR (NP_386600), and SmNitB (NP_384119) were chosen as
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candidates responsible for the nitroreduction of roxarsone and nitarsone (See
the Results and discussion section). For construction of plasmids for expression
of SmazoR, SmnemA, and SmnitB, each gene was PCR-amplified from total
genomic DNA of S. meliloti Rm1021 with PfuTurbo DNA polymerase (Agilent
Technologies Inc., Santa Clara, CA) using the forward and reverse primers listed
in Table 3. Amplicons were digested by NheI and HindIII (SmazoR) or NcoI
and XhoI (SmnemA and SmnitB) and ligated into pET28a, generating the plasmids
pET28a-SmazoR,

pET28a-SmnemA,

and

pET28a-SmnitB.

The

genes

of SmmdaB, SmmsuE, and Smazr were chemically synthesized with 5′ NcoI and
3′ XhoI sites and cloned into pET28a by GenScript Biotech Corp. (Piscataway,
NJ), generating the plasmids pET28a-SmmdaB, pET28a-SmmsuE, and pET28aSmazr.
3.2.4 In vivo nitroreduction of trivalent nitroaromatic arsenicals
In vivo nitroreduction of Rox(III) by E. coli AW3110(DE3) cells carrying the
constructed plasmids was analyzed spectrophotometrically as described
previously (Chen et al., 2019b). Briefly, after overnight growth in LB medium
supplemented with 25 μg mL–1 kanamycin and 0.3 mM isopropyl β-D-1thiogalactopyranoside (IPTG) at 30 °C, the cells were washed once with low
phosphate medium (Oden et al., 1994) supplemented with 0.2% D-glucose and
suspended in glucose-free M9 medium (Deininger, 1990) at a cell density of
A600nm = 10.0. The cell suspensions were then incubated with 60 μM Rox(III) at 30
°C with shaking (200 rpm) for 6 h. The nitroreductase activity of cells was estimated
by loss of absorbance at 410 nm determined with a Synergy H4 Hybrid Multi-Mode
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microplate reader (BioTek Instruments, Inc., Winooski, VT). In vivo nitroreductase
activity of SmMdaB was also analyzed by arsenic speciation. Cell suspensions
of E. coli AW3110(DE3) cells harboring pET28a-SmmdaB prepared at a cell
density of A600nm = 2.0 in the same way were cultured with 4 μM Rox(III) or Nit(III)
at 30 °C with shaking for indicated hours, and arsenic species in the culture
medium were determined by HPLC-ICP-MS as described above.
3.2.5 Protein purification
E. coli BL21(DE3) cells harboring pET28a-SmmdaB were grown in LB
medium containing 50 mg L–1 kanamycin. The cells at an A600nm of 0.6 were induced
by 0.3 mM IPTG and further cultured for 4 h. The cells were then harvested,
suspended in 5 mL per gram of wet cells in Buffer A [50 mM 4morpholinepropanesulfonic acid, 20 mM imidazole, 0.5 M NaCl, 10 mM 2mercaptoethanol, and 20% glycerol (v/v), pH 7.5], and lysed by a single passage
through a French pressure cell at 20 000 psi and treated with 2.5 μL of diisopropyl
fluorophosphate per gram of wet cells. After centrifugation at 150 000g for 1 h, the
resultant supernatant solution was loaded onto a Ni2+-nitrilotriacetic acid column
(Qiagen, Hilden, Germany) at a flow rate of 0.5 mL min–1. The column was washed
with more than 25 column volumes of Buffer A. His-tagged SmMdaB was eluted
with Buffer A with increased concentration of imidazole (0.2 M) and the purity was
analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis. Protein
concentrations were estimated from A280nm (ε = 53 910 M–1·cm–1). SmMdaBcontaining fractions were divided into small portions, rapidly frozen, and stored at
−80 °C until use.
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3.2.6 FAD reductase activity
The amount of flavin adenine dinucleotide (FAD) in purified SmMdaB was
quantified by absorption at 450 nm using a molar extinction coefficient of 11 300
M−1 ·cm−1 . Reduction of FAD by SmMdaB was assayed in 25 mM Bis−Tris
propane buffer (pH 7.0) containing 1 mM EDTA and 0.1 mg mL−1 bovine serum
albumin (BSA) at 37 °C. NADPH (0.2 mM) was incubated with 1 μM SmMdaB
and/or 25 μM FAD and the oxidation of NADPH was monitored by the decrease in
absorbance at 340 nm (ε = 6220 M−1 ·cm−1 ).
3.2.7 In vitro nitroreduction of pentavalent nitroaromatic arsenicals
Nitroreductase activity of SmMdaB was examined in vitro using purified
protein. Rox(V) or Nit(V) (4 μM) was incubated at 37 °C in the presence or absence
of 1 μM SmMdaB in a reaction solution (25 mM Tris, 25 mM Bis-Tris propane (pH
7.0), 1 mM EDTA, 0.1 mg mL−1 BSA, 0.2 mM NADPH and 25 μM FAD) with or
without 5 mM glutathione (GSH) and/or 1 mM tris-(2-carboxyethyl)phosphine
(TCEP). Reactions were collected at the indicated time points, and the arsenic
species were analyzed by HPLC-ICP-MS as described above.
3.3

Results

3.3.1 Reduction of MAs(V) by S. meliloti
The pure culture of S. meliloti Rm1021 is able to reduce MAs(V) to MAs(III)
while the pure culture of Streptomyces sp. MD1 cannot transform MAs(V) (Figure
4A, Table 2). In contrast, co-cultures of S. meliloti Rm1021 and the MAs(III)demethylating microbe Streptomyces sp. MD1 degrade MAs(V) to inorganic
As(III). These reesults are consistent with our concept that microbial communities

46

are capable of sequentially reducing MAs(V) to MAs(III) and demethylating the
MAs(III) to As(III).
3.3.2 Reduction of aromatic arsenicals by S. meliloti
We previously identified the arsI gene for MAs(III) demethylation from
Bacillus sp. MD1, an MAs(III)-demethylating bacterial isolate from Florida golf
course soil (Yoshinaga and Rosen, 2014). Cells of the arsenic-hypersensitive E.
coli strain AW3110 (Carlin et al., 1995) expressing arsI degrade trivalent aromatic
arsenicals, including p-ASA(III), Nit(III), and Rox(III) into inorganic As(III),
suggesting that ArsI also catalyzes aerobic breakdown of these antimicrobial
animal growth promoters. It seemed reasonable to consider that pentavalent
aromatic arsenicals also undergo sequential reduction and ArsI-catalyzed C−As
bond cleavage by microbial communities. This is formally similar to demethylation
of the MSMA herbicide by the MAs(V)-reducing Burkholderia sp. MR1 and the
MAs(III)-demethylating Streptomyces sp. MD1 from Florida golf course soil.
However, neither Burkholderia sp. MR1 nor P. putida KT2440, the other known
MAs(V) reducers, are able to reduce pentavalent aromatic arsenicals (Figure 5).
In contrast, S. meliloti Rm1021 reduces them to the trivalent species. As with
MAs(V), S. meliloti Rm1021 converts most of the p-ASA(V) to trivalent p-ASA(III)
after 3 days (Figure 4B, Table 2). On the other hand, cells of S. meliloti Rm1021
transformed Nit(V) to primarily p-ASA(III) rather than Nit(III) (Figure 4C,D, Table
2). A time-course analysis shows that S. meliloti Rm1021 first reduces the nitro
group of Nit(V), forming p-ASA(V) (Figure 6A,B, 36 h), and subsequently reduces
the arsenate group of p-ASA(V), forming p-ASA(III) (Figure 6B, 48 and 60 h).
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Similarly, S. meliloti Rm1021 transformed Rox(V) primarily to HAPA(III) rather than
Rox(III) (Figure 4E,F, Table 2). The strain first reduces the nitroaromatic group of
Rox(V), transforming it into the pentavalent amine derivative 4-hydroxy-3aminophenylarsonate (HAPA(V)) (Figure 6C,D, 36 h) and subsequently reduces
the As(V) moiety, forming HAPA(III) (Figure 6D, 60 h). Two unknown species are
also produced from Rox(V) (Figure 6C,D) but not Nit(V) (Figure 6A,B). In addition,
cells of S. meliloti Rm1021 produced small amounts of As(III) over time from both
Nit(V) (Figure 6B) and Rox(V) (Figure 6D). Because S. meliloti Rm1021 does not
have an arsI gene, As(III) might be a minor secondary product of reduction of
aromatic arsenicals and/or adventitious C−As bond cleavage by other lyases such
as C−P (carbon-phosphorus) lyases (Parker et al., 1999). In contrast, neither
Burkholderia sp. MR1 nor P. putida KT2440 reduce either the nitro group or As(V)
group (Figure 5). The levels of the pentavalent aromatic arsenicals in the cultures
of Burkholderia sp. MR1 and P. putida KT2440 are comparable to those in culture
medium without cells, suggesting that these strains may not be able to take up
pentavalent aromatic arsenicals. As is the case of MAs(V), a mixed culture of S.
meliloti Rm1021 and Streptomyces sp. MD1 could degrade p-ASA(V) (Figure 4B),
Nit(V) (Figure 4D), and Rox(V) (Figure 4F) into As(III). Given that S. meliloti is a
ubiquitous rhizosphere soil bacterium (Galleguillos et al., 2000) and that arsI genes
are widely distributed from thermophiles (Nadar et al., 2016) to cyanobacteria (Yan
et al., 2015), we propose that this multiple-step aromatic arsenical degradation
pathway exists in the oxic environment and forms a part of the arsenic
biogeochemical cycle.
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3.3.3 Identification of the gene nitroreduction of aromatic arsenicals
Because S. meliloti 1021 first reduces the nitro group and subsequently
reduces the arsenate moiety (Figure 4D,F), we consider the possibility that each
reduction uses a different enzyme. Nitroreduction of aromatic arsenicals has been
observed in anaerobic degradation (Cortinas et al., 2006; Stolz et al., 2007; Han
et al., 2017) indicating that nitroreduction is a critical step in the anaerobic
degradation of environmental aromatic arsenicals. The undA and mtrC genes,
which are involved in iron reduction in Shewanella putrefaciens W3-18-1 strain
(Yang et al., 2013) have been suggested to account in part for anaerobic reduction
of Rox(V) to HAPA(V) by S. putrefaciens CN-32 (Han et al., 2017). From S.
putrefaciens 200, the highly versatile facultative anaerobe carrying a large arsenic
island with a number of genes in several ars operons (Chen and Rosen, 2016) we
recently found a novel bacterial resistance mechanism for trivalent nitroaromatic
arsenicals that is also initiated with nitroreduction (Chen et al., 2019b). Three
linked genes widely distributed in ars operons from anaerobes, named arsEFG,
confers resistance to Nit(III) and Rox(III) by a combination of nitroreduction of
Nit(III) or Rox(III) to p-ASA(III) or HAPA(III) by ArsEF and efflux of p-ASA(III) or
HAPA(III) by ArsG. In contrast, no molecular details are known for nitroreduction
of aromatic arsenicals by aerobes. Possibilities include known bacterial
nitroreductases and azoreductases that have central roles in reduction of
nitroaromatic compounds (Roldán et al., 2008; Suzuki, 2019). Although their
physiological roles remain unclear, these enzymes have gained considerable
attention because of their potential applications in cancer treatment and
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bioremediation. A number of bacterial nitroreductases and azoreductases have
been identified to activate nitroaromatic anticancer prodrugs such as CB1954 (5(aziridine-1-yl)-2,4- dinitrobenzamide) and PR-104A (2-((2-bromoethyl)-2-([(2hydroxyethyl)amino]carbonyl)-4,6-dinitroanilino)ethyl methanesulfonate) (Prosser
et al., 2010; Green et al., 2013; Prosser et al., 2013) and nitroaromatic
antimicrobial prodrugs nitrofurans such as nitrofrazone and nitrofurantoin (Race et
al., 2005; Crescente et al., 2016) and to degrade nitroaromatic environmental
contaminants such as 2,4,6-trinitrotoluene (TNT) (Kutty and Bennett, 2005;
González-Pérez et al., 2007; Liu et al., 2007) Because these nitroaromatic
compounds have similarities with Rox(V) and Nit(V), it was reasonable to consider
that some are capable of reduction of Nit(V) and Rox(V). One candidate is ArsH,
which physiologically oxidizes MAs(III) to MAs(V) for detoxification (Chen et al.,
2015a). ArsH from Pseudomonas aeruginosa PAO1 has been demonstrated to
reduce a nitroaromatic antibiotic (nitrofurazone) to the hydroxylamine derivative
(Crescente et al., 2016). However, a S. meliloti Rm1021 ars operon deletion strain
lacking arsH (Δars) (Yang, 2008; Chen et al., 2015a) retains the ability to reduce
nitroaromatic arsenicals (Figure 7), indicating little or no contribution of SmArsH.
We conducted a BLAST search of the genome of S. meliloti 1021 to identify
orthologs of AzoR, MdaB, MsuE, and NemA enzymes that reduce CB1954 and/or
PR-104A to hydroxylamine derivatives (Prosser et al., 2010; Green et al., 2013;
Prosser et al., 2013). These include SmAzoR (NCBI accession no.: NP_385442),
SmMdaB (NP_387022), SmMsuE (NP_438025), and SmNemA (NP_385670).
There are also homologs of AZR and NitB, enzymes that reduce TNT to
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hydroxylamino-dinitrotoluene (Kutty and Bennett, 2005; Liu et al., 2007) including
SmAZR (NP_386600) and SmNitB (NP_384119). To examine their potential role
in reduction of nitroaromatic arsenicals, each of the above genes were cloned or
synthesized and expressed in E. coli AW3110. Some bacteria, including E. coli,
take up Rox(III) more effectively than Rox(V) (Chen and Rosen, 2016; Chen et al.,
2019b), so reduction of Rox(III) was examined in vivo. Both pentavalent and
trivalent roxarsone absorbs with a λmax = 410 nm at physiological pH, whereas
the corresponding HAPA amine is colorless, which allows nitroreduction to be
monitored by loss of absorption at 410 nm (Figure 8). A significant decrease in
A410nm was observed only in the cultures of cells expressing SmmdaB, so we
focused on SmMdaB for further characterization. Rox(III) biotransformation by
cells expressing SmmdaB was analyzed by HPLC-ICP-MS (Figure 9). In the
culture medium of these cells, Rox(III) was mostly converted to HAPA(III), whereas
no HAPA was produced in the medium of the control cells. The results are
consistent with SmMdaB reduction of roxarsone to HAPA. In T24 human bladder
carcinoma cells, the IC50 values for Rox(III) and HAPA(III) are 0.2 and 22 μM,
respectively (Peng et al., 2017), suggesting that nitroreduction of Rox(III) to
HAPA(III) could be a detoxification process. However, cells expressing SmmdaB,
which transformed Rox(III) to HAPA(III), were not resistant to Rox(III) (data not
shown), suggesting that HAPA(III) is also very toxic to E. coli and nitroreduction
alone does not detoxify Rox(III) in the E. coli cells.
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3.3.4 SmMdaB as a nitroaromatic arsenical reductase
MdaB (modulator of drug activity B) has been shown to be an FAD- and
NADPH-dependent quinone reductase with nitroreductase activity with various
nitroaromatic compounds (Prosser et al., 2013; Crescente et al., 2016).
Nitroreduction by the S. meliloti ortholog SmMdaB was characterized in vitro using
purified protein. Purified SmMdaB is yellow and exhibits an absorption spectrum
with λmax at 450 nm because of 61.2% FAD occupancy. However, it still requires
supplementation with FAD in addition to NADPH to exhibit FAD reductase activity
(Figure 10). SmMdaB requires an additional reducing potential such as GSH or
TCEP for nitroreductase activity with Rox(V) in addition to FAD and NADPH
(Figure 11A). The added reductant may be required to reduce the nitro group all
the way to the amine. In contrast, purified MdaB from P. aeruginosa PAO1
(PaMdaB) catalyzes nitroreduction of nitrofranzone with only NADPH as the
reductant in vitro, but the product is the hydroxylamine derivative and not the amine
(Crescente et al., 2016). No nitroreduction was observed without the enzyme
(Figure 11B). SmMdaB also reduces nitarsone to p-ASA both in vivo (Figure 12)
and in vitro (Figure 13). Altogether, our results clearly demonstrate that SmMdaB
is a nitroarmoatic arsenical nitroreductase. Because S. meliloti Rm1021 first
reduces the nitro group of Rox(V) and Nit(V) to form HAPA(V) and p-ASA(V) before
reducing the arsenate moiety, neither Rox(III) nor Nit(III) are produced throughout
the entire transformation process (Figure 6A,C). We propose that nitroreduction by
SmMdaB may be required for subsequent reduction of the pentavalent arsenic.
Burkholderia sp. MR1 has no MdaB homolog. Although P. putida KT2440 has one
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MdaB homolog (PpMdaB) that shares 41% identities and 59% positives with
SmMdaB, the strain exhibits no nitroreductase activity with nitroaromatic
arsenicals, perhaps due to the poor uptake of those compounds (Figure 5B,C).
BLAST analyses show that none of the reported Rox(V)-degrading anaerobes
such as Alkaliphilus oremlandii (Fisher et al., 2008) and S. putrefaciens (Chen and
Rosen, 2016; Han et al., 2017) carry mdaB genes, whereas Enterobacter sp. CZ1, the only reported Rox(V)-transforming aerobe (Huang et al., 2019), possesses
multiple mdaB genes and the gene products share ∼40% identities and ∼60%
positives with SmMdaB, suggesting that MdaB plays a role in nitroreduction of

Rox(V) and Nit(V) in that organism. However, MdaB homologs from E. coli
(EcMdaB) and Pseudomonas syringae (PsMdaB) share 60% identities and 74%
positives, nevertheless, only EcMdaB exhibits significant nitroreductase activity
with PR-104A (Green et al., 2013), indicating that even minor differences in protein
sequences could account for the substrate selectivity of different MdaBs. The
mdaB genes are widely distributed among both Gram-positive and Gram-negative
bacteria. Structure-function analyses are required to elucidate the determinants of
substrate selectivity. This information will shed light on the impact of MdaB on the
fate of environmental nitroaromatic arsenicals. In contrast to nitroreduction, the
molecular mechanisms of reduction of arsenate group in aromatic arsenicals are
completely unknown. Further studies are required to identify new gene(s)/
protein(s) involved in the arsenate reduction of the growth promoters.
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3.4

Figures and tables

Figure 2. Oxidation of trivalent organoarsenicals. (A, C, F) MAs(III)I2 (A, line 3), p-ASA(III) (C, line
3) and HAPA(III) (F, line 3) prepared as described in Materials and methods were oxidized with
H2O2 (line 2) and compared with the corresponding pentavalent species (line 1) using HPLC-ICPMS. (B, D, E, G) The sole culture of S. meliloti with MAs(V) (B, line 3), Nit(V) (D, line 3), p-ASA(V)
(E, line 3) and Rox(V) (G, line 3) were oxidized with H2O2 (line 2) and compared with standards
(line 1) using HPLC-ICP-MS.

Figure 3. Chemical structure of arsenicals.
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Figure 4. Organoarsenical reduction by S. meliloti Rm1021. Transformation of the indicated
organoarsenicals in the presence or absence of S. meliloti Rm1021 and/or Streptomyces sp. MD1
was assayed by HPLC-ICP-MS, as described under the Materials and methods section. (A)
Transformation of MAs(V) was analyzed using a C18 reverse-phase column. (B) Transformation
of p-ASA(V) was analyzed using a C18 reverse-phase column. (C) Transformation of Nit(V) was
first analyzed with a C4 reverse-phase column because the retention time of nitroaromatic
arsenicals on the C18 column is much longer than the other species. (D) Transformation of Nit(V)
was further analyzed using a C18 column because the C4 column cannot separate As(III), pASA(III), and p-ASA(V). (E) Transformation of Rox(V) was first analyzed with a C4 column because
the retention time of nitroaromatic arsenicals on the C18 column is much longer than the other
species. (F) Transformation of Rox(V) was further analyzed with a C18 column to separate As(III),
HAPA(III), and HAPA(V).
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Table 2. Quantification of arsenic biotransformation

Transformations of organoarsenicals in the indicated culture conditions were assayed in ST-10
medium, as described in Materials and methods. Data are the mean ± SE (n = 3). bND:
nondetectable. cUnknown species are not reflected because their concentrations cannot be
determined due to lack of the standard.
a

Figure 5. Bacterial transformation of aromatic arsenicals. Transformation of p-ASA(V) (A), Nit(V)
(B) and Rox(V) (C) by S. meliloti Rm1021, Burkholderia sp. MR1 and P. putida KT2440 were
assayed by HPLC-ICP-MS with a C18 reverse-phase column (A) or a C4 reverse-phase column (B
and C) as described under Methods and Materials.
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Figure 6. Time-course analysis of the transformation of nitroaromatic arsenicals by S. meliloti
Rm1021. Transformation of Nit(V) (A and B) and Rox(V) (C and D) in cultures of S. meliloti Rm1021
after the indicated times (0, 24, 36, 48, 60 h) was analyzed by HPLC-ICP-MS with a C4 column (A
and C) or a C18 column (B and D) as described under Materials and methods.

Figure 7. Nitroreduction of nitroaromatic arsenicals by a S. meliloti ars operon deletion strain.
Transformation of Nit(V) (A) and Rox(V) (B) by S. meliloti Rm1021 (S. meliloti) and S. meliloti ars
operon deletion strain (S. meliloti Δars) were assayed by HPLC-ICP-MS with a C4 reverse-phase
column as described under Methods and Materials.
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Figure 8. Nitroreduction of Rox(III) by E. coli AW3110 cells expressing candidate nitroreductase
genes. Roxarsone nitroreductase activity of E. coli AW3110 cells that heterologously express each
of the indicated candidate nitroreductase genes was estimated by the decrease of Rox(III) λmax
(A410nm) and compared with that of the non-expressing cells (Control) as described under Methods
and Materials.

Figure 9. Roxarsone nitroreductase activity of SmMdaB in vivo. Nitroreduction of Rox(III)
by SmmdaB-expressing AW3110 cells was analyzed by HPLC-ICP-MS as described under
the Materials and methods section. As described in the legend to Figure 4, arsenic species in the
culture of AW3110 cells carrying pET28a-SmmdaB after the indicated hours was first analyzed by
a C4 column (A) and subsequently analyzed with a C18 column (B) to separate As(III), HAPA(III),
and HAPA(V). Vector, AW3110 cells carrying the empty vector (pET28a); +SmmdaB, AW3110 cells
carrying pET28a-SmmdaB.

58

Figure 10. SmMdaB exhibits NADPH-dependent FAD reductase activity. Purified SmMdaB (1 µM)
was assayed for NADPH:FAD reductase activity with 0.2 mM NADPH and 25 μM FAD, as indicated.
NADPH oxidation was followed from the decrease in absorption at 340 nm.

Figure 11. Roxarsone nitroreductase activity of SmMdaB in vitro. Nitroreduction of Rox(V) by
purified SmMdaB was assayed as described under the Materials and methods section. (A) Effect
of GSH and TCEP on nitroreduction of Rox(V). Nitroreduction of Rox(V) by SmMdaB was carried
out with or without 5 mM GSH and/or 1 mM TCEP, and the products were analyzed by HPLC-ICPMS with a C4 column. (B,C) Nitroreduction of Rox(V) by purified SmMdaB was carried out with 5
mM GSH and 1 mM TCEP and analyzed by HPLC-ICP-MS. As described in the legend to Figure 4,
arsenic species in the reaction mixtures after the indicated time was first analyzed with a C4
reverse-phase column (B) and subsequently analyzed on a C18 column (C) to separate As(III),
HAPA(III), and HAPA(V).
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Figure 12. Nitroreduction of Nit(III) by SmmdaB-expressing AW3110 cells was analyzed by HPLCICP-MS as described under Materials and methods. Arsenic species in the culture after the
indicated hours was first analyzed by a C4 column (A) and subsequently analyzed with a C18
column (B) to separate As(III), p-ASA(III) and p-ASA(V). Vector, AW3110 cells carrying the empty
vector (pET28a); + SmmdaB, AW3110 cells carrying pET28a-SmmdaB.

Figure 13. Nitroreduction of Nit(V) in vitro. 4 µM of Nit(V) was incubated at 37 °C in the presence
(+ SmMdaB) or absence (No enzyme) of 1 μM SmMdaB in a reaction solution and arsenic species
after the indicated hours were analyzed by HPLC-ICP-MS with a C4 column (A) or a C18 column
(B) as described under Methods and Materials.
Table 3. Oligonucleotide primers used in plasmid constructions.
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Figure 14. Degradation of pentavalent aromatic arsenicals by an aerobic microbial community is a
multistep process. S. meliloti takes up pentavalent aromatic arsenicals by unknown transporters,
reduces the nitro group by MdaB and the arsenate moiety by unknown reductases. The trivalent
aminoaromatic arsenical products are extruded from the cells, possibly by ArsK. The secreted
trivalent organoarsenicals act as antibiotics to kill competitors. A small portion of the aromatic
arsenicals are degraded into As(III), which flows out of the cell by ArsK or by downhill movement
through AqpS (Liu et al., 2016). Some community members detoxify the organoarsenical antibiotics
by a variety of organoarsenical resistance mechanisms, as described in the text. S.
meliloti degrades the pentavalent aromatic arsenicals by sequential reduction of the nitro and
arsenate groups. C–As bond cleavage of the trivalent aminoaromatic arsenicals is carried out by
other members of microbial communities such as Streptomyces species that carry an arsI gene.
This is similar to the pathway of reduction of and resistance to the pentavalent methylarsenical
herbicide MSMA.

3.5

Discussion
With the exception of only a few natural products as typified by

chloramphenicol, most nitroaromatic compounds, including roxarsone and
nitarsone, are produced and released into the environment via industrial processes
or other human activities (Roldán et al., 2008). Synthetic nitroaromatic compounds
are substrates for a number of bacterial nitroreductases and azoreductases, which
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play key roles in the degradation/detoxification/cometabolism process, suggesting
that the environmental pollution could have posed a selective pressure for adaptive
rapid evolution of the bacterial enzymes. Alternatively, these enzymes, which are
more ancient than their synthetic substrates, may have evolved to reduce as-yet
unidentified nitroaromatic natural products. We recently showed that arsEFG,
widely distributed in anaerobes, confer resistance to trivalent aromatic arsenicals
but not to other natural occurring inorganic and organic arsenicals (Oden et al.,
1994), which is another example of rapid adaptation to the introduction of
anthropogenic

organoarsenical.

In

this

study,

we

demonstrate

that S.

meliloti Rm1021 is capable of reduction of both the nitro and arsenate groups of
pentavalent nitroaromatic arsenicals, producing trivalent aminoaromatic arsenicals
as final products (Figures 4 and 6). In analogy with methylarsenicals, pentavalent
aromatic arsenicals are much less toxic than inorganic arsenicals, while their
trivalent forms are much more toxic than inorganic species (Chen et al., 2015a),
suggesting that reduction of aromatic arsenicals is also an activation process.
Thus, we propose that S. meliloti Rm1021 has gained the capacity to utilize the
artificial aromatic arsenicals as an antibiotic to enhance their competitive
advantage in contaminated sites—another way of bacterial rapid adaptation to
synthetic arsenical contaminants. Trivalent aromatic arsenicals exhibit higher
toxicity to bacteria compared to MAs(III) (Chen et al., 2015a; Chen et al., 2015b;
Chen et al., 2019b), indicating that trivalent aromatic arsenicals would be more
potent antibiotics and give a better competitive advantage to the reducers. Similar
to the Caco-2 cell (Liu et al., 2016), both Burkholderia sp. MR1 and P.
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putida KT2440 poorly take up pentavalent aromatic arsenicals (Figure 5). Given
that, one of the critical features that enables S. meliloti Rm1021 to reduce
pentavalent aromatic arsenicals should be the effective uptake systems, which will
be an important future research objective to be elucidated. There are several
genes known to confer resistance to trivalent aromatic arsenicals (Figure 14). As
mentioned above, arsEFG confers resistance specifically against trivalent
nitroaromatic arsenicals via sequential reactions of nitroreduction by ArsEF and
extrusion of the resulting amine derivatives by ArsG (Chen et al., 2019b). Both the
MAs(III) oxidase ArsH and the MAs(III) efflux pump ArsP also detoxify Rox(III),
although their catalytic efficiency is relatively lower compared to that for MAs(III)
(Chen et al., 2015a; Chen et al., 2015b). In contrast, the MAs(III) demethylase ArsI
is less selective and effectively degrades both MAs(III) and Rox(III) (Yoshinaga
and Rosen, 2014). In addition, a recent study shows that arsK, the newly
identified ars gene from Agrobacterium tumefaciens GW4 that encodes a novel
arsenic efflux pump (AtArsK), confers resistance to As(III), antimonite (Sb(III)),
MAs(III), and Rox(III) (Shi et al., 2018). Interestingly, S. meliloti 1021 carries
an arsRK operon in one of the two megaplasmids pSymB (Finan et al., 2001).
SmArsK shares 69% identities and 80% positives with AtArsK. SmArsK may
function as an efflux pump for secretion of these trivalent organoarsenical
antibiotics from S. meliloti 1021. In turn, other members of these microbial
communities have acquired the resistance mechanisms described above. Given
the recent but heavy usage of aromatic arsenicals in animal husbandry and the
ubiquity of Sinorhizobium species in the rhizosphere, our results suggest that the
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agricultural application of aromatic arsenicals fuels bacterial competition for
dominance and survival, especially in oxic environments. Microbial breakdown of
organoarsenicals can lead to local arsenic contamination, which can alter the soil
microbiome and retard plant growth.

3.6
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Chapter 4.

4.1

ORGANOARSENICALS INHIBIT BACTERIAL PEPTIDOGLYCAN
BIOSYNTHESIS BY TARGETING THE ESSENTIAL ENZYME
MurA

Introduction
Arsenic is among the most prevalent toxic elements in the environment. Life

first arose in environments with substantial concentrations of inorganic arsenic.
Although evolution of genes for arsenic tolerance was a first priority for primordial
life, the ubiquity of arsenic provided an opportunity for microbes to adapt those
pathways to produce organoarsenical antimicrobial compounds that could give
them a competitive advantage over other members of microbial communities (Zhu
et al., 2014). Microbial arsenic biotransformations include redox cycles,
methylation, thiolation and incorporation into complex organic molecules such as
arsenolipids and arsenosugars, creating a global arsenic biogeochemical cycle
(Zhu et al., 2017). As a result, several organisms produce a variety of arseniccontaining natural products that differ in toxicity. In general pentavalent
methylarsenicals are less toxic than inorganic As(III), with the exception of
thiolated species (Fan et al., 2018) and the recently-discovered pentavalent
organoarsenical antibiotic arsinothricin (Nadar et al., 2019). In contrast, trivalent
organoarsenical natural products such as MAs(III) and dimethylarsenite
(DMAs(III)) are much more toxic than As(III) (Petrick et al., 2000; Naranmandura
et al., 2011; Yoshinaga and Rosen, 2014). These organoarsenicals are products
of the enzyme As(III) S-adenosylmethionine (SAM) methyltransferase (ArsM in
microbes and AS3MT in animals). ArsM is postulated to have co-evolved with the
MAs(III) efflux permease ArsP in an anoxic environment prior to the GOE (Chen
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et al., 2017). We proposed that the antibiotic-like properties of its products provided
a competitive advantage for producers, over other members of anaerobic microbial
communities (Li et al., 2016; Chen et al., 2018). Following the GOE, trivalent
arsenicals were generally oxidized to their less toxic pentavalent forms such as
methylarsenate (MAs(V)). In response, members of aerobic microbial communities
evolved mechanisms to reduce MAs(V), giving them a competitive advantage over
MAs(III)-sensitive microbes (Yoshinaga et al., 2011). Yet other members of aerobic
microbial communities developed oxygen-dependent resistance to MAs(III) such
as ArsH, which oxidizes MAs(III) to MAs(V) (Chen et al., 2015a) and the C-As bond
lyase ArsI, which demethylates MAs(III) to less toxic As(III) (Yoshinaga and Rosen,
2014), suggesting that this competition between microbial communities is a driving
force behind the arsenic biogeocycle. Indeed, the MAs(III) efflux permease ArsP
is another pathway for resistance (Chen et al., 2015b).
The goal of this study was to identify possible targets of MAs(III) inhibition
that can explain its strong antibiotic properties. We chose to search for new genes
in the environmentally ubiquitous gram-negative facultative anaerobe S.
putrefaciens 200 because it has a number of ars operons with many known and
putative genes for arsenic resistance and a wide capacity for organoarsenic
biotransformation and transport, suggesting evolution in an environment
containing MAs(III) (Chen et al., 2015b; Chen and Rosen, 2016). We constructed
a genomic expression library from S. putrefaciens 200 and selected for MAs(III)
resistance clones in E. coli. Overexpression of target enzymes have been shown
to confer resistance to antibiotics such as triclosan, trimethoprim, penicillin, and
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other β-lactams (Henze and Berger-Bächi, 1996; Palmer and Kishony, 2014). One
resistance clone with an insert of 2.8 kb was sequenced and shown to express the
S. putrefaciens murA gene. MurA catalyzes transfer of enolpyruvate from
phosphoenolpyruvate (PEP) to uridine diphosphate N-acetylglucosamine (UDPGlcNAc), the first committed step in peptidoglycan biosynthesis (Barreteau et al.,
2008). Thus, we considered the possibility that MurA is a target of MAs(III), which
could inhibit peptidoglycan biosynthesis, and increasing MurA expression could
overcome the antimicrobial activity of MAs(III). From the use of arsenic-containing
minerals in ancient China to Paul Ehrlich’s synthesis of the aromatic arsenical
salvarsan, the first chemotherapeutic agent for syphilis, arsenic-containing drugs
have been used extensively throughout history (Lloyd et al., 2005; Liu et al., 2008)
In modern medicine, arsenic trioxide (ATO) is an FDA-approved, effective anticancer agent for promyelocytic leukemia (APL) (Ralph, 2008). With the increasing
threats posed by antibiotic resistance, the bacterial peptidoglycan biosynthetic
pathway has been a recent focus for development of new inhibitors (Brackman et
al., 2016; Chang et al., 2017). The identification of cell wall biosynthesis as a target
of MAs(III) affords the prospect for development of new arsenic-containing
antimicrobial agents.
4.2

Materials and methods

4.2.1 Chemicals
All chemicals were obtained from MilliporeSigma (Burlington, MA) unless
otherwise mentioned. For in vivo assays, MAs(V) was reduced to MAs(III) by a
slight modification of a previous procedure (Johnson, 1971). Briefly, 0.2 mM
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MAs(V) was mixed with 27 mM Na2S2O3, 66 mM Na2S2O5, and 82 mM H2SO4,
followed by pH adjustment to 6 using NaOH. For in vitro assays, because the
reagents used to reduce MAs(V) (Na2S2O3, Na2S2O5, and H2SO4) ablated MurA
activity, the methylarsonous acid iodide derivative (MAs(III)I2) was synthesized as
previously described (Stice et al., 2016).
4.2.2 Strains, plasmids, media, and growth conditions
S. putrefaciens 200 used for total DNA extraction was provided to us as a
gift from Flynn Picardal, Indiana University. Expression vector pET26b containing
S. aureus SH1000 (WP_000358012.1) MurA was kindly provided by Dr. Alex
O’Neill (University of Leeds, Leeds, UK). E. coli One Shot™ TOP10 (Thermo
Fisher Scientific, Waltham, MA) (F- mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15
Δ lacX74 recA1 araD139 Δ( araleu)7697 galU galK rpsL (StrR) endA1 nupG) was
used for library construction and in vivo arsenical resistance assays. E. coli strain
BL21 (fhuA2 [lon] ompT gal (λ DE3) [dcm] ∆hsdS λ DE3 = λ sBamHIo ∆EcoRI-B
int::(lacI::PlacUV5::T7 gene1) i21 ∆nin5) was used for expression and purification
of S. putrefaciens 200 wild-type and C117D MurA, as well as in vivo fosfomycin
resistance assays. E. coli strains were grown aerobically at either 30 °C or 37 °C
in either lysogeny broth (LB) or 2x ST medium (20-fold concentrated ST 10-1 media,
10 g l-1 Difco Bacto Peptone and 1 g l-1 yeast extract) supplemented with 0.2%
glucose (Maki et al., 2006).
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4.2.3 Isolation of S. putrefaciens 200 DNA fragment conferring MAs(III)
resistance
To construct a genomic library of S. putrefaciens 200, total DNA was
extracted using DNeasy Blood & Tissue kit (QIAGEN, Hilden, Germany) and
digested with HindIII (New England Biolabs, Ipswich, MA). Following digestion and
ethanol precipitation, the pelleted DNA was suspended in water and layered on a
discontinuous sucrose gradient (10%, 20%, 30%, 40%) buffer containing 50 mM
Tris, adjusted to pH 8.0 by HCl, 0.1 M EDTA, and 0.1 M NaCl. The gradients were
then centrifuged at 210,000 × g for 5 h at 17° C to separate DNA fragments by
size. After centrifugation the solution was carefully removed from the top of the
layer and separated into fractions. Fractions were electrophoresed on 1% agarose
gels to confirm their size, and fractions containing DNA fragments larger than 2
kbp were combined and concentrated via ethanol precipitation. The resulting DNA
fragment mixture was ligated overnight at 16° C into HindIII-digested cloning vector
pUC118 using LONG ligase (TaKaRa, Kusatsu, Japan). Ligase mixture was
transformed into E. coli TOP10 using electroporation, and transformants were
spread on LB media agar plates containing 100 µg/ml ampicillin. Ligation and
transformation steps were repeated twice more to attain a total of 3 plates of
approximately 2,000 colonies each. A glycerol stock of the library was made from
LB plates and aliquoted, followed by flash freezing and storage at -80° C. To
ensure complete coverage of the S. putrefaciens 200 genome during MAs(III)
resistance selection, average fragment sizes were calculated by purifying plasmid
DNA from several transformants using E.Z.N.A.® Plasmid Mini Kit I (Omega Bio-
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Tek, Norcross, GA), and digesting plasmids with HindIII, followed by gel
electrophoresis using 1% agarose gels. Average insert size was found to be 6.7
kbp, hence approximately 2,000 colonies were spread to cover the 5 Mbp of the
S. putrefaciens 200 genome.
Clones were selected for resistance to MAs(III). After obtaining
approximately 2,000 colonies on LB plates, colonies were replicated onto 1, 2, and
3 µM MAs(III) ST 10-1 media (0.5 g l-1 Difco Bacto Peptone and 0.05 g l-1 yeast
extract) agar plates supplemented with 50 µg/ml ampicillin and 0.2% glucose, and
incubated at 30° C for 48 hours. To exclude MAs(III) clones that had acquired the
gene for the ArsP MAs(III)-selective efflux pump (of which S. putrefaciens 200 has
two copies), colonies growing on 2 and 3 µM MAs(III) plates were picked and
analyzed for the presence of the arsP gene by colony PCR using forward primers
GATGATGATCCATGGGGATGAATCCTGAAACCCTAGCC

(arsP1)

and

GATGATGATCCATGGGGATGCTGCAAATATTTTCAGATTTAGCGAGTTGG
(arsP2)

and

reverse

primers

GATGATGATGTCGACGCTAAATACATAGCTATAAAGAAACCCAGAGCCG
(arsP1) and GATGATGATGTCGACCAAAATGGGGCTGATCCCGTT (arsP2).
Colonies lacking arsP genes were assayed for their arsenic biotransformation
capacity using high performance liquid chromatography (HPLC) (Series 2000;
PerkinElmer, Waltham, MA) coupled with inductively coupled plasma mass
spectrometry (ICP-MS) (ELAN DRC-e; PerkinElmer, Waltham, MA) (vide infra). A
single clone isolated lacking both arsP genes and arsenic biotransformation
activity was streaked to confirm homogeneity, plasmid DNA was purified from two
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colonies, and partial sequence information of the insert fragment was determined.
The whole sequence of the insert fragment was obtained through nucleotide
BLAST search against the S. putrefaciens 200 genome (GCA_000169215.2), and
the same fragment was obtained from plasmids of both colonies.
To compare the level of MAs(III) resistance conferred by the DNA fragments
to known MAs(III) resistance mechanisms, pTrcHis2A vector carrying S.
putrefaciens 200 arsP (pTrcHis2A-SpArsP) (Chen et al., 2015b) and pUC19 vector
carrying Bacillus sp. MD1 arsI (pUC19-ArsI) (Yoshinaga and Rosen, 2014) were
transformed into E. coli TOP10 and grown overnight in LB media supplemented
with 100 µg/ml ampicillin. Overnight cultures were washed by 2x ST medium, and
cell density was adjusted to a starting absorbance (A600nm) of 0.05 in 2x ST media
containing indicated concentrations of MAs(III) and supplemented with 50 µg/ml
ampicillin and 0.2% glucose. Cells were incubated at 30° C shaking for 5 hours,
after which growth was estimated from the absorbance at 600nm.
4.2.4 Arsenic transformation by HPLC-ICP-MS
To determine whether the DNA fragment isolated from S. putrefaciens 200
conferred the ability to transform MAs(III) into less toxic species, cells with that
construct were compared with cells expressing the ArsI C–As lyase. E. coli TOP10
cells carrying pUC19-ArsI (Yoshinaga and Rosen, 2014), and two colonies of E.
coli pUC118 cells carrying the S. putrefaciens 200 DNA fragment, and the parent
plasmid (pUC118) were cultured overnight in 3 mL LB media supplemented with
100 μg/mL ampicillin. Overnight cultures were centrifuged and suspended in 2 mL
ST 10−1 medium supplemented with 0.2% glucose containing 2 μM MAs(III). Cells
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were incubated for 4 h at 30 °C. After incubation, culture media was filtered by
centrifugation at 20,000 × g for 10 min at 4 °C using Amicon Ultra Centrifugal Filters
with a 3 kDa membrane (MilliporeSigma, Burlington, MA). Arsenic from filtrates
was speciated by HPLC-ICP-MS using a reverse-phase C18 column (250 mm ×
4.6 mm; Thermo-Fisher, Waltham, MA), as described previously (Qin et al., 2006).
4.2.5 Identifying the gene responsible for MAs(III) inhibition
Tyrosine-to-stop

codon

mutations

were

introduced

individually

into bolA and murA genes in the purified plasmid DNA via site-directed
mutagenesis

using

forward

primers

TCGGATGGTAGCCATTAGAAAGTCATCGCCGTAG-3’

(bolA)

5′and

5′-

CGTTATTGGCACGCTAGGGTACCGCTGACG-3’ (murA) and reverse primers 5′CTACGGCGATGACTTTCTAATGGCTACCATCCGA-3’

(bolA)

and

5′-

CGTCAGCGGTACCCTAGCGTGCCAATAACG-3’

(murA).

Primers

were

designed

primer

design

tool

using

the

QuikChange®

(https://www.agilent.com/store/primerDesignProgram.jsp). For mutagenesis, a
PCR mixture containing 180 ng of template DNA, 0.5 μM of forward and reverse
primers, 2.5 mM of dNTP mix, 5% DMSO, and 100U of Pfu Turbo (with the
appropriate buffer) was used. An initial denaturing step was performed at 94 °C for
5 min, followed by 18 cycles of denaturing (50 s at 94 °C), annealing (50 s at
60.4 °C), and elongation (4 min at 72 °C). A final elongation step was performed
at 72 °C for 10 min. Following mutagenesis, plasmids were digested with DpnI at
37 °C overnight. Digestion mixtures were concentrated and transformed
into E. coli TOP10 using heat-shock. Transformants were spread on LB plates
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supplemented with 100 μg/mL ampicillin and incubated overnight at 37 °C.
Plasmid DNA was purified from several colonies and sequenced using forward
primers 5′-GATGATGATGAGCTCATGGAATGCAGCTTAATCGAACAG-3’ (bolA)
and 5′-GATGATGATGAGCTCATGGCGGGAGTATTGGCAGAGACC-3’ (murA)
and reverse primers 5′-GATGATGATCGGCCGTCACTAGCTAGGCATGTTGAA3’ (bolA) and 5′-GATGATGATCGGCCGTTATTGTACGCGCTCTACATGCGC-3’
(murA). After obtaining the appropriate mutants, MAs(III) resistance assays were
assayed in 2x ST media, as described previously. DNA sequencing was performed
by Sequetech (Mountain View, CA).
4.2.6 S. putrefaciens 200 MurA expression and purification
Codon-optimized S. putrefaciens 200

wildtype murA was

commercially

synthesized and cloned into expression vector pET28a (GenScript, Piscataway,
NJ). This construct was transformed into E. coli BL21 using heat-shock.
Transformants were cultured in 10 mL of LB media supplemented with 25 μg/mL
kanamycin and incubated at 37 °C overnight. An overnight culture was used to
inoculate 1 L of LB media supplemented with 25 μg/mL kanamycin, and MurA
expression was induced using 0.3 mM of Isopropyl β-d-1-thiogalactopyranoside
(IPTG) for 1.5 h at 37 °C at an A600 nm = 0.6. Cells were collected and suspended
in 5 mL per gram of wet cells in buffer A (50 mM MOPS, 20% glycerol (vol/vol),
0.5 M NaCl, 20 mM imidazole, 10 mM 2-mercaptoethanol). Cells were broken by
a single passage through a French press cell at 20,000 psi. The cell lysate was
ultra-centrifuged at 160,000 × g for 1 h at 4 °C, and the supernatant was loaded
onto a nickel-NTA resin column (Thermo-Fisher Scientific, Waltham, MA) at a flow

79

rate of 1.0 mL/min. The column was washed with buffer A and eluted with buffer A
containing 100 mM imidazole. MurA purity was analyzed by sodium dodecyl
sulfate (SDS) polyacrylamide gel electrophoresis (PAGE), and fractions containing
MurA were combined and concentrated using an Amicon Ultra-30 centrifugal filter
(MilliporeSigma, Burlington, MA) by centrifugation at 5,000 × g. Imidazole was
removed from MurA fractions by diluted to sub-micromolar concentrations and
concentration twice with buffer A without imidazole. Protein concentration was
estimated using the Bradford assay using bovine serum albumin as standard
(Bradford, 1976). MurA was aliquoted, flash frozen, and stored at -80° C.
A cysteine 117 to aspartic acid (C117D) mutation was introduced into the
expression construct via site-directed mutagenesis. Primers used were 5’ATTGCCGGGCGGCGATGCCATTGGCGCG-3’

(forward)

and

5’-

CGCGCCAATGGCATCGCCGCCCGGCAAT-3’ (reverse). Plasmid digestion with
DpnI, purification, and sequencing was performed as described previously, as
were expression and purification of C117D MurA.
4.2.7 In vitro MurA activity and inhibition
MurA activity was determined from the release of inorganic phosphate (Pi)
with purine-nucleoside phosphorylase (PNP), as previously described with minor
modifications (Blake et al., 2009). Briefly, 760 μl of reaction mixture containing
50 mM HEPES, 100 μM dithiothreitol (DTT), 90 nM MurA, 300 μM UDP-Nacetylglucosamine (UDP-GlcNAc), 250 μM 7-methyl-6-thioguanosine (MESG),
0.1U/mL PNP and inhibitors (Fos, MAs(III), PhAs(III)) was added to wells on a 96well plates (190 μL), and the reaction was started by adding 10 μl of 2 mM
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phosphoenolpyruvate (PEP) at a final concentration of 100 μM. The increase in
absorbance at 360 nm was monitored at room temperature in real time using a
Synergy™ H4 (BioTek, Winooski, VT) plate reader. For co-incubation of MAs(III)
(50 μM) and N-ethylmaleimide (NEM) (450 μM), DTT was removed from the
reaction mixture to allow for NEM binding to cysteine residues, and mixtures were
incubated with NEM for 15 min at room temperature prior to adding MAs(III).
4.3

Results

4.3.1 Selection of an S. putrefaciens 200 gene that confers MAs(III)
resistance
Most bacterial genes involved in arsenic detoxification and transformation
are found in ars operons; however, we expected that the targets of antimicrobial
compounds such as MAs(III) would more likely be unrelated to arsenic
biochemistry. Thus, to isolate potential targets of MAs(III) inhibition, a genomic
library of S. putrefaciens 200 was constructed and expressed in E. coli. Selection
for resistance to 3 μM MAs(III) yielded a colony (Clone 1) that was confirmed to
confer MAs(III) resistance after purification by streaking onto LB agar plates
(Figure 15). Clone 1 did not biotransform MAs(III) (Figure 16). Plasmid DNA was
isolated from Clone 1, and the DNA insert was sequenced and aligned to the S.
putrefaciens 200 genome (Accession number GCA_000169215.2). A 2.8 kilobase
pair fragment was identified, which contained two full-length open reading frames
that were annotated as bolA encoding a transcriptional regulator, and murA,
annotated to encode a UDP-N-acetylglucosamine enolpyruvyl transferase. Neither
gene was in an ars operon of S. putrefaciens 200, and neither has been previously
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reported to be involved in arsenic resistance. To determine which of these genes
confers the MAs(III)-resistant phenotype, stop codons were introduced via sitedirected mutagenesis into the sequences of each gene. Cells carrying the mutant
bolA plasmid remained resistant to MAs(III), whereas cells carrying the mutant
murA plasmid lost resistance (Figure 17), demonstrating that murA is responsible
for the MAs(III)-resistance phenotype.
4.3.2 MurA is selectively inhibited by organoarsenicals
MurA catalyzes the first committed step of bacterial peptidoglycan
biosynthesis and is essential for both gram-negative and gram-positive bacteria
(Barreteau et al., 2008). The enzyme catalyzes the transfer of the enolpyruvate
moiety of phosphoenolpyruvate (PEP) to the 3’ hydroxyl group of UDP-Nacetylglucosamine

(UDP-GlcNAc),

generating

UDP-N-acetylglucosamine-

enolpyruvate and inorganic phosphate (Pi) (Eschenburg et al., 2003). SpMurA was
purified from cells of E. coli and assayed for Pi release using a coupled assay
(Webb, 1992; Blake et al., 2009). MurA activity was inhibited by MAs(III) but not
inorganic As(III) (Figure 18). The aromatic organoarsenical PhAs(III) inhibited
MurA more strongly than MAs(III), consistent with the observation that aromatic
arsenicals have higher affinity for arsenic-binding enzymes than MAs(III)
(Pawitwar et al., 2017).
4.3.3 Cysteine 117 is not required for organoarsenical inhibition of SpMurA
activity
MurA is inhibited by the broad-spectrum antibiotic fosfomycin (Fos) (Kahan
et al., 1974), which is a competitive inhibitor of PEP that covalently binds to a
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cysteine residue conserved in most but not all bacterial species (Figure 19).
Overexpression of MurA confer resistances to Fos (Couce et al., 2012). Growth of
cells of E. coli expressing a wild-type S. putrefaciens 200 murA gene was inhibited
by Fos (Figure 20A). Similarly, the activity of purified wild-type MurA was inhibited
by Fos (Figure 20B). The murA gene of Mycobacterium tuberculosis has an
aspartic acid residue in the position of this cysteine, and this bacterium is resistant
to Fos (De Smet et al., 1999). E. coli cells, which have a chromosomally-encoded
wild-type EcMurA with Cys115, are sensitive to Fos, and a C115D mutation has
been shown to confer Fos resistance (Kim et al., 1996). To examine whether
Cys117 in SpMurA is involved in organoarsenical inhibition of S. putrefaciens 200
MurA, Cys117 was changed by mutagenesis to an aspartic acid residue. Cells
expressing the C117D mutant are resistant to Fos (Figure 20A), and purified
SpMurAC117D was not inhibited by Fos (Figure 20B). In contrast, both wild-type
SpMurA and the C117D derivative are equally sensitive to inhibition by either
MAs(III) or PhAs(III) (Figure 21). These results indicate that Cys117 is not involved
in inhibition by trivalent organoarsenicals, suggesting that MAs(III) and fosfomycin
have different mechanisms of action.
4.3.4 Organoarsenical inhibition of SpMurA involves cysteine residues
While Cys117 is apparently not involved in MAs(III) inhibition, S.
putrefaciens 200 MurA and various homologs have several other non-conserved
cysteine residues (Figure 19). SpMurA has eight other cysteine residues in
addition to Cys117. To examine whether any cysteine residues are involved in
organoarsenical inhibition, purified SpMurA activity assayed in the presence of the
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cysteine modifying reagent N-ethylmaleimide (NEM), which completely inhibited
enzymatic activity (Figure 22). In contrast, MurA from Staphylococcus aureus
(SaMurA) contains only the single conserved cysteine. The SamurA gene was
expressed in E. coli, and SaMurA purified. SaMurA was sensitive to Fos (Figure
23) but relatively resistant to trivalent organoarsenicals compared with SpMurA
(Figure 24). These results are consistent with our idea that the conserved cysteine
residue is not involved in MAs(III) inhibition, in contrast to its role in Fos inhibition.
These results indicate that organoarsenicals, while not dependent on the canonical
conserved cysteine used for PEP binding, still inhibit MurA in a cysteine-dependent
manner, and that one or more of the other cysteine residues in MurA sequences
may play a structural role or be otherwise indirectly involved in catalysis.
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Figure 15. DNA isolated from an S. putrefaciens 200 genomic library confers MAs(III) resistance.
Overnight cultures of E. coli TOP10 carrying either, pUC118-Clone 1 (■), pUC19-ArsI (○),
pTrcHis2A-ArsP (▼), or plasmid pUC118 (●) were adjusted to a starting absorbance at 600 nm of
0.05 in 2x ST media supplemented with 0.2% glucose containing the indicated concentrations of
MAs(III). Growth was estimated from A600 nm after 5 h of incubation at 30 °C. Data are the
mean ± SE (n = 3).
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Figure 16. Arsenic transformation by fragment isolated from S. putrefaciens 200 genomic library.
Overnight cultures of E. coli TOP10 cells carrying pUC118-Clone 1 (Clone 1), pUC19-ArsI (ArsI),
or the parent plasmid pUC118 (Vector) were collected and washed and resuspended by ST 10-1
media supplemented with 0.2% glucose. 2 µM of MAs(III) was added to the culture media and
samples were incubated at 30 °C for 4 h. HPLC-ICP-MS was done as described in Materials and
methods. The x-axis represents the retention time of various arsenicals through a C18 column, and
the y-axis represents relative amounts of arsenic expressed in counts per second (cps).
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Figure 17. Expression of murA confers resistance to MAs(III) in vivo. Overnight cultures
of E. coli TOP10
carrying
either
pUC118-Clone
1,
which
contains
wildtype S. putrefaciens 200 murA and bolA (●), vector carrying a murA tyrosine-to-stop codon mutant
(Δ), vector carrying a bolA tyrosine-to-stop codon mutation (▼), or parental plasmid pUC118 (○)
were adjusted to a starting A600 nm of 0.05 in 2x ST media supplemented with 0.2% glucose
containing the indicated concentrations of MAs(III). Growth was estimated from the A600 nm after 5 h
incubation at 30 °C. Data are the mean ± SE (n = 3).
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Figure 18. SpMurA
is
selectively
inhibited
by
organoarsenicals.
Purified
wildtype S. putrefaciens 200 SpMurA and UDP-N-acetylglucosamine (UDP-GlcNAc) were incubated
with purine-nucleoside phosphorylase (PNP) and its substrate, methylthioguanosine (MESG),
whose purine base product absorbs at λ = 360 nm. The reaction was initiated by addition of PEP
at a final concentration of 0.1 mM, and the release of Pi in the absence (○) or presence of 20 μM
As(III) (▼), 20 μM MAs(III) (Δ), or 20 μM PhAs(III) (■) was monitored by the increase in A360 nm.
Data were normalized to the activity of the control reaction lacking MurA (●). Data are the
mean ± SE (n = 3).
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---PKAVNIKTAPYPGFPTDMQAQFCVLNALAQGTATITETIFENRFMHVPELIRMGATM
---KGGVLLETDVHPGFITDWQQPFAVLLSQSEGCSVIHETVHENRLGYLKGLVKMGAHC
DFGGHIPKIDDGPWPAFPTDLMSIIVVTATQVEGTVLVFEKMFESRMFFVDKLIKMGARI
---PKAVNVATLPFPGFPTDLQPMAIALASIADGTSMITENVFEARFRFVEEMIRLGADA
---PKAVNVRTAPYPAFPTDMQAQFISMNAVAEGTGAVIETVFENRFMHVYEMNRMGAQI
---PKAVNVRTAPHPAFPTDMQAQFTLLNLVAEGTGFITETVFENRFMHVPELSRMGAHA
---LKAVNIRTAPHPAFPTDMQAQFTLLNMMAKGSGIITETIFENRFMHIPELQRMGAHA
---LQPVDIKTLPHPGFPTDMQSQMMALLLTANGHKVVTETVFENRFMHVAEFKRMNANI
---LKAVHVKTLPHPGFPTDMQAQFTALMTVAKGESTMVETVFENRFQHLEEMRRMGLHS

Figure 19. MurA sequence alignment of bacterial strains. The protein sequence of S. putrefaciens
200 MurA (WP_011790698.1) is compared with MurA homologs studied in existing literature. The
source strain and NCBI accession number (in parenthesis) of aligned sequences are Chlamydia
trachomatis L2 (AGJ64824.1), Borreliella burgdorferi B31 (NP_212606.2), Mycobacterium
tuberculosis R37v (WP_003406845.1), Pseudomonas aeruginosa PA01 (NP_253140.1),
Escherichia coli K-12 (WP_000357281.1), Aliivibrio fischeri MJ11 (3VCY_A), Staphylococcus
aureus SH1000 (WP_000358012.1), and Streptococcus pneumoniae R6 (WP_000358027.1).
Multiple
sequence
alignment
was
done
using
Clustal
Omega
(https://www.ebi.ac.uk/Tools/msa/clustalo/). Amino acids shown in black or gray indicate sequence
identity or similarity, respectively. Cysteine residues within each sequence are highlighted in yellow,
and the conserved cysteine required for fosfomycin inhibition is indicated by a red asterisk.
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Figure 20. In vivo and in vitro inhibition of wild-type and C117D S. putrefaciens 200 SpMurA by
fosfomycin. (a) To confirm SpMurA overexpression confers fosfomycin resistance in vivo, overnight
cultures of E. coli BL21 cells carrying pET28a-MurA wild-type (○) or the C117D mutant (▼), and
the parent plasmid (●) were diluted 100-fold and induced with 0.3 µM of IPTG for 90 min. Following
induction, cells were adjusted to a starting growth (A600nm) of 0.05 in 2x ST media supplemented
with 0.2% glucose containing the indicated concentrations of fosfomycin. Growth was measured
after a 5 h incubation at 30 °C. (b) To confirm that wild-type SpMurA is inhibited by fosfomycin, and
that the C117D mutant is resistant in vitro, purified SpMurA proteins were incubated with one of its
substrates, UDP-N-acetylglucosamine (UDP-GlcNAc) and with purine-nucleoside phosphorylase
(PNP) along a b its substrate, methylthioguanosine (MESG), whose purine base product absorbs
at λ = 360nm. The reaction was started by addition of the second MurA substrate
phosphenolpyruvate (PEP), and the release of inorganic phosphate (Pi) from the MurA reaction in
the absence ((○), wild-type; (▼), C117D) or presence of 1 µM fosfomycin ((■), wild-type; (Δ),
C117D) was monitored by the increase in absorbance at 360nm (A360nm). Data was normalized
to the activity of the control reaction lacking MurA (●). Data are the mean ± SE (n = 3).
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b

Figure 21. Cys117 is not required for organoarsenical inhibition. The C117D SpMurA was purified,
and inhibition by MAs(III) compared with wild-type SpMurA. As described in the legend to Figure
18, activity of SpMurA was monitored in the absence ((o), wild-type; (▼), C117D) or presence of
either MAs(III) (a) or PhAs(III) (b) at either 10 μM ((Δ), wild type; (□), C117D) or 50 μM ((■), wild
type; (♦), C117D). Data were normalized to the activity of the control reaction lacking MurA (●).
Data are the mean ± SE (n = 3).
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Figure 22. NEM modification of cysteine residues in SpMurA results in loss of activity. Purified wild
type SpMurA was assayed, as described in the legend to Figure 18., in the presence (○) or absence
(▼) of NEM or in the presence of both 50 μM MAs(III) and 450 μM NEM (Δ). Data were normalized
to the activity of the control reaction lacking MurA (●). Data are the mean ± SE (n = 3).
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Figure 23. In vitro inhibition of S. aureus SH1000 MurA (SaMurA) by fosfomycin. To confirm that
the MAs(III)-resistant SaMurA is sensitive to fosfomycin, purified SaMurA was used for
organoarsenical inhibition. MurA and one of its substrates, UDP-N-acetylglucosamine (UDPGlcNAc), were incubated with purine-nucleoside phosphorylase (PNP) and its substrate,
methylthioguanosine (MESG), whose purine base product absorbs at λ = 360 nm. The reaction
was started by addition of the second MurA substrate, phosphenolpyruvate (PEP), and the release
of inorganic phosphate (Pi) from the MurA reaction in the absence (○) or presence of fosfomycin at
1 µM (▼), 2 µM (Δ), or 5 µM (■) was monitored by the increase in A360 nm. Data was normalized
to the activity of the control reaction lacking MurA (●). Data are the mean ± SE (n = 3).
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Figure 24. A MurA ortholog with a single conserved cysteine confers trivalent organoarsenical
resistance. Purified S. aureus SaMurA that contains only the single conserved cysteine required
for fosfomycin inhibition was assayed for organoarsenical inhibition in the absence (○) or presence
of either MAs(III) (a) or PhAs(III) (b) at 100 μM (▼), 200 μM (Δ), or 500 μM (■). Data were
normalized to the activity of the control reaction lacking MurA (●). Data are the mean ± SE (n = 3).
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4.5

Discussion
MAs(III) has antibiotic-like properties and is produced by a number of

bacterial species in microbial communities as a way to gain a competitive
advantage (Chen et al., 2018). Trivalent arsenicals, including As(III) and MAs(III),
have rather nonspecific toxic effects by depletion of cellular glutathione and small
thiol proteins such as thioredoxin and glutaredoxin (Lin et al., 2001), and inhibition
of thiol-containing enzymes such as lipoamide dehydrogenase (Bergquist et al.,
2009). These shut down energy metabolism and increase reactive oxygen species.
However, targets specific for bacteria, which could be used for the development of
new antibiotics or antimicrobial drugs, have not been identified. In this report we
identify the inhibition of MurA UDP-N-acetylglucosamine enolpyruvyl transferase
by the trivalent natural product MAs(III) and the synthetic organoarsenical
PhAs(III), and propose their antibiotic properties are at least partially a result of this
inhibition.
As the first committed step in that pathway, MurA is an essential enzyme
for many bacteria, which makes it an excellent drug target. Several classes of
inhibitors such as sesquiterpene lactones, 2-aminotetralones and quinazolinones
have been developed against MurA (Bachelier et al., 2006; Dunsmore et al., 2008;
Hrast et al., 2017). MurA is also inhibited by fosfomycin, a broad-spectrum
antibiotic used to combat Staphylococci, Pseudomonads, and other enteric gramnegative

pathogens

complete E. coli open

(Raz,
reading

2012).

A

frame

genome-wide

library
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the

the

only
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overexpression, and resistance is achieved at a low fitness cost (Couce et al.,
2012).

Nonetheless,

only

a

few

reports

have

described

enhanced murA expression associated with fosfomycin resistance in clinical
isolates, suggesting that overexpression of murA is rare in clinical settings
(Castañeda-García et al., 2013). However, the mechanism of action of those MurA
inhibitors requires a cysteine residue that is conserved in many but not all bacteria.
Species that lack the conserved cysteine residue such as M. tuberculosis are
resistant to these antibiotics (De Smet et al., 1999). Furthermore, in limited cases,
even MurA orthologs that possess the conserved cysteine exhibit fosfomycin
resistance via other amino acid substitutions (Kumar et al., 2009; Takahata et al.,
2010). Thus, it is important to develop new antibiotics that act on MurA
independent of the consensus cysteine residue. Thus, it is important to develop
new antibiotics that act on MurA independent of the consensus cysteine residue.
It is significant that trivalent organoarsenicals do not require the consensus
cysteine residue to inhibit the S. putrefaciens 200 MurA enzyme. We propose that
inhibition of peptidoglycan biosynthesis is the primary bacterial target of the
biologically generated antibiotic MAs(III). Future goals are to determine how
MAs(III) binds to and inhibits SpMurA, and to examine whether MurA inhibition by
trivalent organoarsenicals is widespread among pathogenic bacteria. These
studies will advance our understanding of arsenical targets in bacteria and provide
valuable information to design new MurA inhibitors.
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Chapter 5.
5.1

A PRELIMINARY STUDY ON THE SUBSTRATE SELECTIVITY OF
THE TRIVALENT ORGANOARSENICAL PERMEASE ArsP

Introduction
Arsenic permeases and efflux pumps are among the most common and

most efficient mechanisms of arsenic detoxification, especially in bacteria
(Garbinski et al., 2019). These transport systems are generally either substrateselective, transporting one arsenic species more efficiently than others, or
substrate-specific. Most arsenic efflux systems confer resistance to trivalent
arsenicals, with the exception of ArsJ, which confers resistance to As(V) when
coupled to glyceraldehyde 3-phosphate dehydrogenase (GAPHD) (Chen et al.,
2016). Arsenic transporters can be found across various protein families; While the
As(III)-specific antiporter Acr3 (Villadangos et al., 2012) and the antimonite
(Sb(III))/As(III) antiporter ArsB (Meng et al., 2004) are both commonly found in ars
operons and serve a similar physiological function, Acr3 is a member of the
bile/arsenite/riboflavin transporter (BART) family, whereas ArsB belongs to the ion
transporter superfamily (Garbinski et al., 2019). This diversity suggests that
arsenic detoxification by efflux transporters is an ancient pathway that has since
evolved to include a wide variety of substrates, and it is likely many more
transporters and their substrates remain undiscovered. With the recent
identification of the organoarsenical antibiotic arsinothricin (AST) (Nadar et al.,
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2019), we predict that a transporter of this natural product is able to confer AST
resistance to the producer strain.
Organoarsenicals are arsenic compounds with one or more aliphatic,
riboside, or aromatic side chain(s), and the recent discovery and characterization
of several enzymes involved in degradation, transport, and synthesis of these
compounds suggests that they are a major component of the arsenic biogeocycle.
Organoarsenical compounds can be products of bacterial metabolism as well as
anthropogenic. Trivalent arsenicals like MAs(III) are natural product antibiotics,
synthesized by bacteria to obtain a competitive advantage in their microbial
communities (Chen et al., 2019a). Recently, it has been proposed that even
synthetic organoarsenicals like Rox(V) and Nit(V) can be “re-activated” by soil
bacteria, increasing their toxicity, and subsequently extruding them (Chen et al.,
2019b; Yan et al., 2019).
Among the first ars genes to evolve were the As(III) S-adenosylmethionine
(SAM) methyltransferase or ArsM, which converts As(III) to MAs(III), DMAs(III) and
TMAs(III), and an associated transporter ArsP (Chen et al., 2020). ArsP was first
identified from roxarsone-resistant Campylobacter jejuni strains (Shen et al.,
2014), where inactivation of this transporter resulted in loss of resistance, and
expression into a C. jejuni strain lacking arsP conferred resistance and decreased
accumulation of roxarsone. Originally, it was proposed to be a novel roxarsone
resistance mechanism due to its prevalent use in animal husbandry; however, it
was later shown that ArsP transports MAs(III) much more efficiently than Rox(III)
(Chen et al., 2015). Given the co-evolution of ArsM and ArsP, it is hypothesized

100

that the synthesis of MAs(III) and subsequent efflux by ArsP gives microbial
communities a competitive advantage, where they use MAs(III) as an antibiotic
(Chen et al., 2019a).
ArsP is thought to belong to the major facilitator superfamily (MFS) of
transporters, yet is predicted to contain eight transmembrane helices (Shen et al.,
2014; Chen et al., 2015); not the twelve which are commonly found in other MFS
transporters (Yan, 2015). ArsP has two conserved cysteine residues which are
critical for resistance and transport of organoarsenicals (Chen et al., 2015);
however, no residues involved in the selectivity of MAs(III) over aromatic
arsenicals have been identified. In this study, we aim to test the existing
hypotheses for how ArsP selectively transport MAs(III). Firstly, because it has been
suggested that two conserved proline residues flanking the substrate binding site
are involved in a conformational change that occurs on substrate binding (Chen et
al., 2015), we predicted that these prolines may cause steric hindrance of binding
of large aromatic arsenicals to the substrate binding site. We show that individual
prolines are not critical for MAs(III) resistance; however, cells expressing ArsP
lacking both prolines show a significant decrease in its resistance profile. Next, we
considered whether the stronger affinity of aromatic arsenicals for vicinal cysteines
compared to MAs(III) (Pawitwar et al., 2017) impacts the ability of ArsP to extrude
these compounds. We hypothesized that introducing bulkier and/or more
hydrophobic amino acid residues between the substrate binding cysteines would
lower the binding affinity, and thus increase the resistance profile for aromatic
arsenicals; however, all the examined amino acid substitutions resulted in a large
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decrease or loss of resistance. Together, these data suggest that the responsible
residues/motifs for the MAs(III) of ArsP are likely found outside the predicted
substrate binding site, and further structural and topological assays are needed to
elucidate its properties.
5.2

Materials and methods

5.2.1 Chemicals
Unless otherwise indicated, all chemicals were of analytical or better grade
from MilliporeSigma (Burlington, MA). Rox(V) was purchased from Thermo Fisher
Scientific (Waltham, MA). Rox(III) was prepared by chemical reduction of their
corresponding pentavalent forms as previously described (Yoshinaga and Rosen,
2014). In brief, 0.2 mM pentavalent arsenical was mixed with 27 mM Na2S2O3, 66
mM Na2S2O5, and 82 mM H2SO4, following which the pH was adjusted to 6 with
NaOH. The methylarsonous acid iodide derivative (MAs(III)I2) synthesized as
described (Stice et al., 2016) was used as MAs(III).
5.2.2 Strains, media, and growth conditions
Escherichia coli strain TOP10 (Invitrogen, Waltham, MA) used for plasmid
replication and mutagenesis was cultured in lysogeny broth (LB) at 37 °C in a
shaking incubator at 200 rpm. E. coli strain AW3110(DE3) (Δars) (Carlin et al.,
1995) used for in vivo MAs(III)/Rox(III) resistance assays was cultured in either LB
or M9 minimal media (48 μM Na2HPO4 · 7H2O, 22 μM KH2PO4, 8.5 μM NaCl, 18.6
μM NH4Cl, 2 mM MgSO4, 100 μM CaCl2) supplemented with 0.2% glucose. 100
μg/ml ampicillin was added as necessary in each culture.
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5.2.3 Assaying effect of substrate binding site mutations
Expression vector pTrcHis2A-SpArsP (pTrcHis2A carrying the gene that
encodes Shewanella putrefaciens 200 ArsP (SpArsP, WP_014610144.1)) (Chen
et al., 2015) was utilized as a template for all mutagenesis experiments. Mutations
in the gene were carried out by PCR mutagenesis with primers designed using the
QuikChange®

primer

design

(https://www.agilent.com/store/primerDesignProgram.jsp).

Briefly,

tool
a

reaction

mixture containing 180 ng of template DNA, 0.5 μM of forward and reverse primers,
2.5 mM of dNTP mix, 5% DMSO, and 10U of Pfu Turbo (Agilent Technologies,
Santa Clara, CA) with the provided buffer was run with the following PCR cycle
conditions. An initial denaturing step was performed at 94 °C for 5 min, followed
by 18 cycles of denaturing (50 s at 94 °C), annealing (50 s at 64.4 °C), and
elongation (6.5 min at 72 °C). A final elongation step was performed at 72 °C for
10 min. The codons for the proline residues in the predicted MAs(III)-binding site
of SpArsP (Pro69 and Pro77) were individually mutated to alanine codons,
generating derivatives P69A and P77A. A mutant with both prolines changed to
alanine (P69/77A) was also created. The codon for the serine residue between the
substrate binding cysteines Cys71 and Cys73 (Ser72) was mutated to alanine,
valine, tyrosine, cysteine, or leucine, generating S72A, S72V, S72Y, S72C, and
S72L. The primers used for mutagenesis are as follows, forward primers: 5’–
TGGAGCAAGAACAAAATGCGGTAATAGACCCAAGTAG–3’

(P69A),

5’–

AAGTAGACCTTTTAAGAACGCAATAGTGGAGCAAGAACAAAATG–3’ (P77A),
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5’–GTCTATTACCCCATTTTGTGCTTGCTCCACTATTCCGT–3’

(S72A),

5’–

ACTTGGGTCTATTACCCCATTTTGTGTTTGCTCCACTATTCCGT–3’ (S72V), 5–
ACTTGGGTCTATTACCCCATTTTGTTATTGCTCCACTATTC–3’

(S72Y),

5–

ACTTGGGTCTATTACCCCATTTTGTTGTTGCTCCACTATTC–3’ (S72C), and 5–
GCTACTTGGGTCTATTACCCCATTTTGTTTATGCTCCACTATTCCG–3’ (S72L);
reverse primers: 5’–CTACTTGGGTCTATTACCGCATTTTGTTCTTGCTCCA–3’
(P69A), 5–CATTTTGTTCTTGCTCCACTATTGCGTTCTTAAAAGGTCTACTT–3’
(P77A)

5’–ACGGAATAGTGGAGCAAGCACAAAATGGGGTAATAGAC–3’

(S72A),

5’–

ACGGAATAGTGGAGCAAACACAAAATGGGGTAATAGACCCAAGT–3’ (S72V),
5’–GAATAGTGGAGCAATAACAAAATGGGGTAATAGACCCAAGT–3’

(S72Y),

5’–GAATAGTGGAGCAACAACAAAATGGGGTAATAGACCCAAGT–3’

(S72C),

and 5’–CGGAATAGTGGAGCATAAACAAAATGGGGTAATAGACCCAAGTAGC–
3’ (S72L). The proline double mutant was generated by sequential mutagenesis
using the primers listed above. Each PCR reaction was digested with DpnI, at 37
°C overnight. Digestion mixtures were concentrated and transformed into E. coli
TOP10 using heat-shock. Transformants were spread on LB plates supplemented
with 100 μg/ml ampicillin and incubated overnight at 37 °C. Plasmid DNA was
purified from several colonies and sequenced using forward vector primer
pSE3805 (5’–GGCTCGTATAATGTGTGG–3’) and reverse vector primer pSE3083
(5’–GGCATGGGGTCAGGTGGG–3’) to confirm the mutations. DNA sequencing
was performed by Sequetech (Mountain View, CA).
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5.2.4 Organoarsenical resistance assay
AW3110(DE3) E. coli cells bearing pTrcHis2A (control) or pTrcHis2A-SpArsP
(wild-type or mutant derivatives) were cultured overnight in LB supplemented with
100 μg/ml ampicillin at 37 °C in a shaking incubator at 200 rpm. Overnight cultures
of SpArsP-expressing cells were washed and diluted to an A600 nm of 0.045 in M9
minimal media supplemented with 0.2% glucose and 100 μg/ml ampicillin, while
the control cells were diluted to an A600 nm of 0.03. After a 30-minute recovery
period, where cells were incubated at 37 °C in a shaking incubator at 200 rpm,
indicated concentrations of MAs(III) or Rox(III) were added and incubated at 30 °C
for 24 hours. After the incubation, cell growth was estimated from the absorbance
at 600 nm.
5.3

Results and discussion

5.3.1 Proline residues flanking binding site are not critical for resistance
The ArsP substrate binding motif (Table 4) is a highly conserved sequence
of amino acids, which contains two absolutely conserved prolines. In membrane
proteins, proline residues are common within transmembrane α-helices (Barlow
and Thornton, 1988), and have been shown to twist the normal structure of helices
by “kinking” the portions of the helices adjacent to the proline residue (Chang et
al., 1999). In transporters, conformational changes on substrate binding which shift
the protein from an “i” state with an open pore facing the cytosol, to an “e” state
with the pore facing the extracellular space or the periplasm are suggested to be
the molecular basis for transport (Klingenberg, 1981). Therefore it has been
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proposed that the conserved prolines in the ArsP substrate-binding motif, Pro69
and Pro77, kink the substrate binding helix from an inward-facing conformation to
an outward-facing conformation (Chen et al., 2015), facilitating the transport of
organoarsenicals. To test this hypothesis, we constructed E. coli cells expressing
single and double mutants of Pro69 and Pro77 in SpArsP and examined the effects
on the substrate selectivity. Either of the single mutants did not lose resistance to
MAs(III), whereas the double mutant showed a decrease in the MAs(III) resistance
profile (Figure 25). Furthermore, these mutants showed less resistance to Rox(III)
when compared to the wild type (Figure 26).
We hypothesized that a pair of conserved proline residues flanking the
substrate-binding cysteines kink the helix, causing conformational changes that
drive transport of organoarsenicals. However, individual proline residues were not
critical to confer resistance to neither MAs(III), nor Rox(III). The proline doublemutant did show a pronounced loss of resistance, though this may be due to lower
protein expression, or structural aberrations. These conserved proline residues
also do not seem to sterically hinder Rox(III) entry into the binding site, as neither
of the mutants showed a stronger Rox(III)-resistant phenotype than the wild-type.
5.3.2 Aromatic arsenical affinity to cysteines is not responsible for MAs(III)
selectivity
Substrate binding sites in some bacterial ars proteins, such as ArsR (Chen
et al., 2014) and ArsI (Pawitwar et al., 2017), have higher affinity for trivalent
aromatic arsenical compounds compared to MAs(III). Thus, another possibility
would be that efflux of trivalent aromatic arsenicals is less efficient due to stronger
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interactions with the catalytic cysteines, hindering trivalent aromatic arsenicals
from being preferable substrates for SpArsP. Therefore, we substituted Ser72, the
conserved serine located between the two catalytic cysteines Cys71 and Cys73
(Table 4, highlighted in light green) to larger, smaller, or more hydrophobic
residues, which we hypothesize weakens the strong affinity of the substratebinding cysteines and increases the efficiency of SpArsP for trivalent aromatic
arsenical substrates. However, all the Ser72 mutation derivatives became more
sensitive to MAs(III) (Figure 27). Differential MAs(III) resistance profiles were
observed, with the strongest reduction in resistance caused by greatly increasing
bulk, and the least caused by modifying hydrophobicity. These mutants were also
less resistant to Rox(III); however, the serine-to-valine mutation had the least
pronounced effect on resistance (Figure 28), similar to the profile for MAs(III).
Since low-affinity substrates can be transported at a higher rate than highaffinity substrates (Severance et al., 2017), it is possible that if the dissociation of
substrates from the ArsP binding site is the rate-limiting step. Thus, substrates
bound with higher affinity will be extruded less efficiently thus conferring lower
amounts of resistance. When we mildly disrupted the substrate binding site by
altering the properties of Ser72, we observed differing resistance profiles to
Rox(III) depending on the substitution. However, none conferred higher resistance
to Rox(III) than the wild-type protein. Furthermore, similar resistance profiles were
observed in the presence of MAs(III), suggesting that the conserved Ser72 has a
role for the basis of the transport mechanism rather than the substrate selectivity.
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5.4

Figures and tables

Table 4: Alignment of predicted substrate binding sites for bacterial ArsP homologs (mutated
prolines highlighted in yellow, mutated serine in green)

Species
C. jejuni
S. putrefaciens
V. harveyi
P. proteolyticum

Sequence Alignment
...TPFCSCSTIPLL…
...TPFCSCSTIPFL…
...TPFCSCSTIPFL…
...TPFCSCSTIPFL…
Pro69 Ser72

Pro77

Figure 25: MAs(III) liquid media resistance profile of E. coli AW3110 containing ArsP wild-type and
proline mutants. Single proline mutations in the predicted substrate binding site do not compromise
the MAs(III)-resistant phenotype, whereas the double mutant shows stunted growth Data are the
mean ± SE (n = 3).
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Figure 26: Rox(III) liquid media resistance profile of E. coli AW3110 containing ArsP and proline
mutants. Each proline mutant shows a differential resistance profile to Rox(III), with the double
mutant showing the most stunted growth. Data are the mean ± SE (n = 3).

Figure 27: Effect of site-directed mutagenesis on conserved serine residue in predicted substrate
binding site on MAs(III) resistance phenotype. Except for the valine substitution, each mutation
introduced yielded a partially stunted MAs(III) resistance profile. Data are the mean ± SE (n = 3).
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Figure 28: Effect of site-directed mutagenesis on conserved serine residue in predicted substrate
binding site on Rox(III) resistance phenotype. Contrary to hypothesis that disrupting substrate
binding site would yield higher Rox(III) resistance, with the exception of the valine substitution,
each mutation introduced yielded a loss of the Rox(III) resistance phenotype. Data are the mean
± SE (n = 3). Growth of each strain normalized to growth of no Rox(III) control.

5.5

Significance and future directions
Commercially used pentavalent compounds such as monosodium

methylarsenate (MSMA) accumulate in soil and can leach into groundwater
(Whitmore et al., 2008; Matteson et al., 2014). In soil, MSMA can also be reduced
to methylarsenite (MAs(III)) (Yoshinaga et al., 2011), which is significantly more
toxic than its inorganic counterpart (Petrick et al., 2000; Petrick et al., 2001). In
addition, more complex aromatic organoarsenical compounds such as roxarsone
and nitarsone used as antibiotics and growth promoters for livestock also have
toxic trivalent forms and can be biologically degraded into inorganic arsenic, thus
accumulating in the environment and ending up in the food chain (Fisher et al.,
2015; Nachman et al., 2017). In vitro arsenic biotransformations by cecum
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microflora have been observed, and perturbations to gut microbiota composition
have been correlated with lower inorganic arsenic detoxification capacity and
higher arsenic toxicity in mice models (Kubachka et al., 2009; Lu et al., 2013; Lu
et al., 2014), suggesting that bacterial arsenic metabolism may be directly related
to individual arsenic resistance profiles in humans. The methylarsenite-selective
transporter ArsP is, one of the few transporters currently known to confer
resistance

specifically

to

organoarsenicals,

and

it

is

unique

among

organoarsenical transporters as it can transport several structurally different
species of trivalent organoarsenicals. However, it transports and confers
resistance to MAs(III) more effectively than aromatic arsenicals like Rox(III),
Nit(III), and p-ASA(III) (Chen et al., 2015).. It has been well established that
substrate specificity and selectivity can be altered by modification of amino acid
residues inside and outside substrate binding sites (Vasudevan et al., 2001;
Vandenberg et al., 2007; Gökirmak et al., 2012; Srikant et al., 2020).
Understanding the basis of selectivity of ArsP would give insight into the molecular
basis for organoarsenical binding to transport proteins, and would help us identify
either substrates for putative transporters in ars operons, or transporters for newly
discovered organoarsenicals such as arsinothricin (Kuramata et al., 2016; Nadar
et al., 2019). Furthermore, this data is necessary to the development of better
bioremediation and/or arsenic detection strategies (Mohammed et al., 2011). The
development of organoarsenic-specific biosensors (Chen et al., 2014), or
genetically engineered arsenic bioaccumulating strains (Mateos et al., 2006) take
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us closer to the goal of bettering public health and reducing the risk that arsenic
compounds pose.
Our results suggest that the molecular basis for selectivity of ArsP is likely
outside of the substrate binding site. While determining the crystal structure of
ArsP by X-ray crystallography or cryo-electron microscopy (CryoEM) would yield
the most descriptive data about its transport mechanism, feasibility of this
approach is a concern. Alternatively, scanning alanine mutagenesis (SCAM),
which introduces sequential alanine residues in the amino acid sequence via
mutagenesis has been previously utilized to determine critical residues (Childers
et al., 2007). Screening alanine mutants for a more Rox(III)-resistant phenotype,
followed by modeling of the 3D structures of these mutants would allow us to better
assess whether steric hindrance plays a role in substrate selectivity.
5.6
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Chapter 6.
6.1

SIGNIFICANCE AND FUTURE PROSPECTS

Organoarsenic-based antibiotics
There is a wealth of information on the environmental prevalence, negative

health effects and epidemiology of inorganic arsenic that spans decades. In
contrast, organoarsenical metabolites were only detected in human urine in 2000
(Aposhian et al., 2000), and the first mechanism behind bacterial synthesis of
organoarsenical compounds was first described in 2006 (Qin et al., 2006). Since
then, many genes involved in organoarsenic metabolism and have been identified,
and the proteins they encode characterized (Zhu et al., 2017). However, the
discovery of novel organoarsenical compounds has been slower. Recently, a nonproteinogenic arsenic-containing glutamate analog was identified in arsenic
metabolites of a bacterial isolate from the rice rhizosphere (Kuramata et al., 2016).
This compound is the arsenic analog of the commercially used broad-spectrum
herbicide phosphinothricin (PT) and was named arsinothricin (AST). While PT and
AST both act as irreversible glutamine synthetase inhibitors, AST is 10-fold more
effective as an antibiotic against pathogens like Mycobacterium and Enterobacter
compared with PT. (Nadar et al., 2019). Even before AST was discovered, a gene
annotated to encode a phosphinothricin N-acetyltransferase was found in many
ars operons, raising the question: Why would a gene involved in phosphate
metabolism be present in ars operons? It is expected that the function of ars genes
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would be related to arsenic-containing compounds, not phosphate-containing
compounds. Indeed, the gene (now more appropriately annotated as arsN1)
encodes an N-acetyltransferase found to acetylate AST with higher affinity
compared to PT, and bacteria expressing this gene are resistance to AST (Nadar
et al., 2019). Currently, the search for new organoarsenic-based antibiotics is
limited by the general inaccessibility of analytical techniques that can detect the
various metabolites and intermediates that are likely a biproduct of synthesis. The
idea that compounds like AST belong to a novel class of antibiotics, and that their
biosynthetic pathways are unknown also poses a challenge when utilizing modern
computational predictive methods like genomic mining, as the accuracy of
annotations across genomes is likely not sufficient to identify AST orthologs. Given
that bacteria evolved in an arsenic-rich environment since the dawn of life (Chen
et al., 2020), and that they often harness its toxicity to compete against other
bacteria (Chen et al., 2019a), it is likely that many yet-to-be discovered
organoarsenicals may have untapped potential to be lead antibiotic candidates.
6.2

Unknown ars genes
Since the discovery of the first arsenite resistance mechanisms in bacterial

operons (Rosen and Borbolla, 1984), there has been considerable effort to identify
and characterize bacterial mechanisms of arsenic metabolism. Since the
identification of the first ars genes in the early 1980, the alphabet has been nearly
entirely assigned to new genes (Table 1). With the growing availability of bacterial
genomes, it has become more feasible to scan ars operons to find gene pairs or
clusters and experimentally probe their function (Chen et al., 2016; Chen et al.,

118

2019b). While many genes in ars operons have vague annotations. Even after
cloning, their function remains unclear. One possibility for this observation is that
the substrates of the enzymes/transporters/regulators encoded by such genes
remain unknown, and the function cannot be derived simply from the annotation.
This is particularly applicable to a group of transporters belonging to the major
facilitator superfamily (MFS) found in ars operons, many of which have been
characterized (Garbinski et al., 2019). Another possibility is that these genes are
part of larger clusters and carry out an intermediate step in the overall reaction.
One approach is to create a bacterial growth medium from arsenic-rich soil extracts
and identify metabolites found in the soil that serve as substrates for the
uncharacterized gene products. Overall, identifying and characterizing ars operons
broadens our understanding of the capacity for bacterial arsenic metabolism and
allows us to design new strategies such as biosensors (Chen et al., 2014) to limit
exposure to this toxic metalloid.
6.3

Conclusions and significance
The goals of the research presented in this dissertation were to 1) identify

how aromatic arsenicals elicit antimicrobial activity in the environment, 2) find
cellular targets involved in bacterial organoarsenical toxicity, and 3) further
characterize the ArsP permease, the most efficient resistance mechanism to
organoarsenicals currently known. I investigated the capacity for Sinorhizobium
meliloti Rm1021 to transform aromatic arsenicals such as roxarsone and found
that S. meliloti Rm1021 is capable of activating them by reduction to trivalent
forms. I identified the key bacterial cell wall synthesis enzyme MurA as a target of
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trivalent organoarsenicals and found that organoarsenicals inhibit using a different
mechanism than current antibiotics that target MurA. Finally, I probed the substrate
binding site of the ArsP permease by mutagenesis and found that highly conserved
residues originally hypothesized to play a major role in transport are not essential.
While the data presented here inches us forward in our understanding of
organoarsenical metabolism in the environment, several gaps in our knowledge
must be addressed to have a complete picture.
Arsenic, as a ubiquitous, non-essential environmental toxin, has provided
selective pressure to survive in and utilize arsenic since the beginning of life on
earth. As a result, nearly all living organisms have mechanisms to detoxify arsenic
(Zhu et al., 2014). In particular, bacterial biotransformations of arsenic create a
complex biogeocycle of arsenic in the environment. Redox and methylation cycles,
thiolation, and synthesis of arsenic-based antibiotics create a web of both potential
hazards and benefits to human health.
As a health hazard, the U.S. Environmental Protection Agency (EPA) and
the International Agency for Research on Cancer (IARC) classify arsenic and
arsenic compounds as Group A and Group 1, respectively, designating them as
carcinogenic to humans. In particular, skin cancers such as basal cell and
squamous cell carcinomas have been linked to arsenic exposure and arsenic
content in urine (Hsueh et al., 1997). Furthermore, exposure to arsenic in drinking
water has also been correlated to neurodevelopmental impairment in children and
adolescents, as well as incidence and mortality of cardiovascular disease,
especially among smokers (Chen et al., 2011; Rodríguez-Barranco et al., 2013).
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Due to these adverse health effects, and its prevalence in the environment, the
Agency for Toxic Substances and Disease Registry (ATSDR) has consistently
ranked arsenic as the top priority contaminant (https://www.atsdr.cdc.gov/spl/).
Paracelsus, the father of classical pharmacology, is credited with the adage
"The dose makes the poison". This is interpreted to mean that a compound that is
toxic at high dose can be a medicine at lower dosages, as long as kills the cancer
cell or pathogen before it kills the host. Because of its toxicity, arsenic has a variety
of medicinal uses: being a main line therapy for acute promyelocytic leukemia (LoCoco et al., 2013), used in the “magic bullet” antisyphilitic drug Salvarsan (Lloyd
et al., 2005), and recently showing promise in the treatment of multidrug-resistant
pathogens with the discovery of the non-proteinogenic organoarsenical glutamate
analog arsinothricin (Nadar et al., 2019). While the mechanisms of its anticancer
properties are a topic of debate, it is well-documented that, throughout history,
natural arsenic-containing minerals such as realgar and orpiment have been used
in traditional medicine (Liu et al., 2008). Arsenic and arsenic-based compounds,
like a double-edged sword, have the potential to be candidates for new therapeutic
agents, while also posing serious health threats to communities around the globe.
Observing microbial arsenic metabolism allows us to study both aspects of
arsenic biology. One of the first mechanisms of arsenic resistance that evolved in
bacteria is methylation (Chen et al., 2020). Using the As(III) S-adenosylmethione
methyltransferase ArsM, early anaerobes could detoxify As(III) through three
rounds of methylation, yielding the non-toxic gaseous product trimethylarsine,
which is volatile and leaves the cells in its gaseous form (Qin et al., 2006). The
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trivalent intermediates of As(III) methylation are significantly more toxic than As(III)
(Yoshinaga and Rosen, 2014). As a result, bacteria evolved an efflux permease,
ArsP, specific for these trivalent intermediates which gained them a competitive
advantage in microbial communities (Chen et al., 2019a). This suggests that
methylarsenite (MAs(III)) was produced as a primordial antibiotic. Surprisingly,
bacteria can also “re-activate” synthetic aromatic arsenic compounds even though
these compounds have only been in the environment for less than 100 years. In
the third chapter of this dissertation, I reported our characterization of the capacity
for a soil legume symbiont, Sinorhizobium meliloti Rm1021, to transform
methylarsenicals, as well as aromatic arsenicals. We found that S. meliloti Rm1021
can reduce the nitro group of pentavalent aromatic arsenicals such as Rox(V) and
Nit(V), followed by reduction of the arsenic group, yielding the toxic intermediates
HAPA(III) and p-ASA(III). Furthermore, we identified mdaB as the gene
responsible for the reduction of the nitro group and determined that it is a
FAD/NADPH-dependent nitroreductase with broad substrate selectivity for
nitroaromatic compounds, requiring an electron donor like glutathione (GSH) to
effectively reduce Rox(V). The mechanism by which S. meliloti Rm1021 can
reduce the arsenic group remains unknown; however, these results suggest that
environmental microbes can utilize existing cellular machinery to transform
aromatic arsenicals to gain a competitive advantage, further showing the
complexity of the arsenic biogeocycle and suggesting that this biotransformation
should be considered when determining the environmental implications of
roxarsone use.
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With the recent discovery of arsinothricin from the rice rhizosphere
(Kuramata et al., 2016) and its newfound potential as an antimicrobial drug
targeting multi-drug resistant (MDR) pathogens (Nadar et al., 2019), it is clear that
there is untapped potential for new classes of organoarsenical antibiotics that are
yet-to-be discovered. Even in the case of MAs(III), a primordial antibiotic (Chen et
al., 2019a), there were no known cellular targets to explain its antibiotic properties.
In the fourth chapter of this dissertation, we identified the first enzyme in the
peptidoglycan biosynthesis pathway, MurA, as a target of aliphatic and aromatic
arsenicals. We observed that overexpression of MurA conferred resistance to
MAs(III), a phenomenon that had been previously observed with other antibiotics
(Couce et al., 2012), and that purified enzyme activity was inhibited by either
MAs(III) or the aromatic arsenical phenylarsenite (PhAs(III)), but not by As(III).
Furthermore, we compared the mechanism of organoarsenical inhibition to the
well-characterized, clinically relevant antibiotic fosfomycin, and found that a
conserved cysteine required for fosfomycin inhibition of MurA is not required for
organoarsenical inhibition. MurA homologs with low cysteine content in their amino
acid sequence were observed to be more resistant to organoarsenical inhibition,
suggesting that arsenicals bind to MurA in a cysteine-dependent manner. These
findings suggest that the antimicrobial properties of MAs(III) can be attributed in
part to cell wall synthesis inhibition and highlight the potential for new
organoarsenical derivatives to serve as antimicrobial candidates.
Nobel Laureate Paul Ehrlich, who discovered the antisyphilitic drug
Salvarsan, famously said: “Drug resistance follows the drug like a faithful shadow”
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(Ebrahim, 2010). ArsN1 was discovered even before the broad-spectrum antibiotic
AST. ArsN1 was then was shown to be an AST-selective N-acetyltransferase that
confers resistance to AST (Nadar et al., 2019). Similarly, multiple resistance
mechanisms to MAs(III) have been identified: demethylation to As(III) by the C –
As lyase ArsI (Yoshinaga and Rosen, 2014), oxidation to MAs(V) by the
organoarsenical oxidase ArsH (Chen et al., 2015a), and efflux by the MAs(III)selective permease ArsP (Chen et al., 2015b). ArsP is unique among arsenic efflux
systems as it transports MAs(III) with high efficiency. It can also transport and
confer resistance to the trivalent aromatic arsenicals Rox(III), Nit(III) and pASA(III). The structural and topological properties of ArsP as well as the
mechanisms behind its selectivity are a topic of debate. In the fifth chapter of this
dissertation I tested two major hypotheses for ArsP selectivity for MAs(III): 1) A
pair of highly conserved cysteines flanking the substrate binding site are proposed
to kink the substrate-binding helix into an inward- and outward-facing
conformation, facilitating transport, and 2) aromatic arsenicals bind with higher
affinity to the vicinal cysteine pair in the ArsP substrate binding site, reducing
transport efficiency for these compounds. I found that mutating each of the
conserved prolines individually to alanine did not affect the level of MAs(III)
resistance conferred by ArsP. However, mutating both prolines simultaneously
caused a significant decrease in MAs(III) resistance. Furthermore, neither single
proline-to-alanine mutants nor the double mutant showed higher resistance to
Rox(III), suggesting that these residues are not required for MAs(III) selectivity. In
addition, mild disruption of the substrate binding site by mutation of a conserved
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serine residue located directly between the substrate binding cysteines did not
yield a higher Rox(III) resistant phenotype. Instead, more severe disruptions to the
substrate binding site ablated MAs(III)/Rox(III) resistance. These results indicate
that residues involved in the selectivity of ArsP for MAs(III) may be located outside
the substrate binding site. The detailed mechanism of transport remains to be
elucidated. Structural or topological studies of this transporter would yield the most
descriptive data to understand both of these properties. Better understanding
organoarsenical resistance mechanisms is critical for our ability to develop
potential organoarsenical bioremediation methods and detection systems like
biosensors (Chen et al., 2014). Furthermore, chemical modification of either
resistance mechanisms or the antibiotic arsenical itself could allow development
of combination therapies for microbial infections, highlighting the potential of new
organoarsenical discovery.
In summary, this dissertation summarizes the current knowledge of
bacterial organoarsenical metabolism and provide new perspectives on future
uses of organoarsenical compounds. I highlight the current limitations of the
studies performed and suggest alternative approaches which have the possibility
to yield novel and descriptive data. Lastly, I challenge the view of arsenic as strictly
a poison and suggest that the medicinal properties of arsenic have positively
changed the field of modern medicine, and new arsenical drugs have the potential
to do more in the future.
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